Back to GetFilings.com



Table of Contents



SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


Form 10-K


     
þ
  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
    For the year ended December 31, 2002
 
or
 
o
  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
    For the transition period from           to           .

Commission File Number 000-31803


Transmeta Corporation

(Exact name of registrant as specified in its charter)
     
Delaware
  77-0402448
(State of Incorporation)   (IRS Employer Identification No.)

3990 Freedom Circle, Santa Clara, CA 95054

(Address of Principal Executive Offices, including zip code)

(408) 919-3000

(Registrant’s Telephone Number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.00001 par value per share
Stock Purchase Rights

     Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes þ         No o

     Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.    þ

     Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2).    Yes þ         No o

     As of June 28,2002, the aggregate market value of the shares of common stock held by non-affiliates of the Registrant (based on the average bid and asked prices price of $2.35 for the common stock as quoted by the Nasdaq National Market on that date,) was approximately $250,580,726.

     As of March 21, 2003, there were 138,530,976 shares of the Registrant’s common stock, $0.00001 par value per share, outstanding. This is the only outstanding class of common stock of the Registrant.

DOCUMENTS INCORPORATED BY REFERENCE

     Portions of the Registrant’s definitive Proxy Statement for its Annual Meeting of Stockholders to be held in May 2003 are incorporated by reference into Parts II and III of this report on Form 10-K.




TABLE OF CONTENTS

PART I
Item 1. Business
Item 2. Properties
Item 3. Legal Proceedings
Item 4. Submission of Matters to a Vote of Security Holders
PART II
Item 5. Market for Registrant’s Common Equity and Related Stockholder Matters
Item 6. Selected Financial Data
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Item 8. Financial Statements and Supplementary Data
REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED STATEMENTS OF OPERATIONS
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
PART III
Item 10. Directors and Executive Officers of the Registrant
Item 11. Executive Compensation
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 13. Certain Relationships and Related Transactions
Item 14. Controls and Procedures
PART IV
Item 15. Exhibits, Financial Statement Schedules and Reports on Form 8-K
SIGNATURES
POWER OF ATTORNEY
CERTIFICATIONS
CERTIFICATIONS
EXHIBIT 23.01
EXHIBIT 99.01
EXHIBIT 99.02


Table of Contents

TRANSMETA CORPORATION

FISCAL YEAR 2002 FORM 10-K

INDEX

             
Item Page


PART I
Item 1
  Business     2  
Item 2
  Properties     9  
Item 3
  Legal Proceedings     9  
Item 4
  Submission of Matters to a Vote of Security Holders     11  
PART II
Item 5
  Market for Registrant’s Common Equity and Related Stockholder Matters     11  
Item 6
  Selected Financial Data     12  
Item 7
  Management’s Discussion and Analysis of Financial Condition and Results of Operations     13  
Item 7A
  Quantitative and Qualitative Disclosures About Market Risk     35  
Item 8
  Financial Statements and Supplementary Data     36  
Item 9
  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure     65  
PART III
Item 10
  Directors and Executive Officers of the Registrant     65  
Item 11
  Executive Compensation     65  
Item 12
  Security Ownership of Certain Beneficial Owners and Management     65  
Item 13
  Certain Relationships and Related Transactions     65  
PART IV
Item 14
  Controls and Procedures     65  
Item 15
  Exhibits, Financial Statement Schedules and Reports on Form 8-K     66  
    Signatures     69  

      We were incorporated in California in March 1995 and reincorporated in Delaware in October 2000. Our principal executive offices are located at 3990 Freedom Circle, Santa Clara, California 95054, and our telephone number at that address is (408) 919-3000. Transmeta®, the Transmeta logo, Crusoe®, the Crusoe logo, Code MorphingTM, LongRun® and MidoriTM are trademarks of Transmeta Corporation in the United States and other countries. All other trademarks or trade names appearing in this report are the property of their respective owners.

1


Table of Contents

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

      This Report contains forward-looking statements that are based upon our current expectations, estimates and projections about our industry, and that reflect our beliefs and certain assumptions based upon information made available to us at the time of this Report. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “could,” “will” and variations of these words or similar expressions are intended to identify forward-looking statements. Such statements include, but are not limited to, statements concerning anticipated trends or developments in our business and the markets in which we operate, the competitive nature and anticipated growth of those markets, our expectations for our future performance and the market acceptance of our products, our ability to migrate our products to smaller process geometries, and our future gross margins, operating expenses and need for additional capital.

      Investors are cautioned that such forward-looking statements are only predictions, which may differ materially from actual results or future events. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Some of the important risk factors that may affect our business, results of operations and financial condition are set out and discussed below in the section entitled “Risks That Could Affect Future Results.” You should carefully consider those risks, in addition to the other information in this Report and in our other filings with the SEC, before deciding to invest in our company or to maintain or change your investment. Investors are cautioned not to place reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this Report. We undertake no obligation to revise or update any forward-looking statement for any reason.

PART I

 
Item 1.      Business

Overview

      Transmeta Corporation develops and sells software-based microprocessors and develops additional hardware, software and system technologies that enable manufacturers to build highly efficient computing systems characterized by low power consumption, reduced heat dissipation and the high performance required to run standard x86 compatible programs. We originally developed our family of Crusoe microprocessors for lightweight notebook computers and other mobile computing devices, but we have developed and are continuing to develop microprocessors suitable for a variety of existing and emerging end markets in which x86 program compatibility and energy and thermal efficiency are desirable.

The Microprocessor Market

      The microprocessor market includes at least two categories, which are distinguished by the basic function of the microprocessor. A microprocessor that performs general computing tasks is known as the central processing unit (CPU) of a computer system. A microprocessor used for control applications is often referred to as an embedded processor. We have historically supplied processors in the CPU category and have focused particularly on supplying energy efficient microprocessors for notebook and other mobile personal computers (PCs). More recently, in January 2003, we publicly announced our line of Crusoe Special Embedded (SE) processors, which are energy efficient microprocessors suited for embedded applications.

      A CPU processor is an integrated circuit, generally consisting of millions of transistors, that serves as the brain of a computer system, such as a PC. The CPU processor is typically the component most critical to the performance and efficiency of PCs. The CPU processor controls data flowing through the electronic system and manipulates data as specified by the hardware and software that controls the system. In 1981, International Business Machines Corporation (IBM) introduced its first PC containing a microprocessor based upon the x86 instruction set developed by Intel Corporation and utilizing the Microsoft Corporation MS-DOS® operating system. As circuit design and large scale integration process technology have evolved, the performance and functionality of each new generation of x86 microprocessors have increased. Personal computers that retained software compatibility with the x86 computer instruction language have thrived, while

2


Table of Contents

those that tried to use other microprocessors incompatible with the x86 PC have not sustained significant market share. In addition to compatibility with standalone x86 PC software, the ability to access the entire Internet and obtain the full Internet experience usually requires x86 compatibility. The x86 microprocessor market has been dominated by Intel since IBM’s introduction of the PC.

      The x86 microprocessor market is characterized by intense competition, short product life cycles and rapid advances in product design and process technology. Today, we believe that the greatest demand for microprocessors is from PC manufacturers. With few exceptions, PC manufacturers require x86 microprocessors that are compatible with Microsoft Windows® operating systems. Improvements in the performance characteristics of microprocessors and decreases in production costs resulting from advances in process technology have broadened the market for PCs and, as a result, increased the demand for microprocessors.

      The market in which PC original equipment manufacturers (OEMs) operate is intensely competitive. Most PC suppliers have evolved from fully integrated manufacturers with proprietary system designs to vendors focused on building brand recognition and distribution capabilities. Almost all of these suppliers now rely on Intel or other third-party manufacturers for the major subsystems of their PCs, such as the motherboard and chipsets. These suppliers are also increasingly outsourcing the design and manufacture of complete systems. The third-party manufacturers of these subsystems, based primarily in Asia, are focused on providing PCs, motherboards and complementary chipset devices that incorporate the latest trends in features and performance at low prices. Increasingly, these third-party manufacturers are also supplying fully configured PC systems through alternative distribution channels.

      Embedded processors also comprise a significant segment of the microprocessor market. Embedded processors are general purpose devices that perform dedicated applications with limited or no user interface and programmability. A system designed around an embedded processor is typically preprogrammed to execute a specific task or function, making it a closed system which cannot be programmed by an end user. Markets for embedded processors include industrial automation, scientific instrumentation, retail kiosks, point-of-sale terminals, automotive infotainment, process control and home automation systems.

Transmeta’s Product Technologies

      We develop and sell software-based microprocessors and develop additional hardware, software, and system technologies that enable manufacturers to build highly efficient computing systems characterized by low power consumption, reduced heat dissipation and the high performance required to run standard x86 compatible programs. We originally developed our family of Crusoe microprocessors for lightweight notebook computers and other mobile computing devices, but we have developed and are continuing to develop microprocessors suitable for a variety of existing and emerging end markets in which x86 program compatibility and energy and thermal efficiency are desirable.

      Our approach to microprocessor design implements substantial portions of the microprocessor functionality in software. Our microprocessors are unique because, unlike traditional microprocessors that are built entirely with silicon hardware, they are composed of both software and hardware components. When combined, these two components form a microprocessor solution that is compatible with software programs designed for x86 PC compatible computers, operates using less power than most other x86 microprocessors and runs standard PC software and Internet applications. We believe that there are several technical and economic benefits to this approach. By partitioning the complex problem of designing a microprocessor into two pieces, each piece is individually simpler to implement. A substantial portion of the functionality of our microprocessor is implemented with software, which allows the remaining functionality to be implemented in a relatively simple semiconductor chip.

      We have developed substantial technical expertise and technology in the following core elements of our microprocessors:

  •  Code Morphing Software. The software component of our microprocessors is called Code Morphing software, because it dynamically translates, or morphs, x86 instructions into instructions for our very long instruction word processors. Code Morphing software dynamically translates from the ones and

3


Table of Contents

  zeros of the x86 software instructions into a functionally equivalent but simpler set of ones and zeros for our hardware chip to decode and execute. The technology involved in Code Morphing software is similar to that used in advanced compilers, but with the input being binary programs rather than high-level language source code. Code Morphing software translates small groups of instructions incrementally, on an as-needed basis. Once a group of instructions is translated, those translated instructions are cached for successive executions without the need for further translation. Since instructions in an application often execute millions of times or more, performance costs associated with translation are quickly amortized. Code Morphing software constantly monitors the programs a user is running in order to re-optimize the operation of those programs so as to maximize the energy efficiency and performance of our microprocessors.
 
  •  Very Long Instruction Word (VLIW) Processor Hardware. The hardware component of our microprocessors is a VLIW processor chip. Our VLIW chip is responsible for basic arithmetic computation, and the control and caching functions. It currently supports 128-bit and 64-bit wide instructions, and will support 256-bit instructions for our next generation TM8000 processor. Each of these wide instructions can control multiple functional units in parallel for high performance under software control. For example, a single 128-bit VLIW instruction might simultaneously control an integer addition, an integer subtraction, a memory load and a branch. Our microprocessors currently employ a number of advanced features. Our microprocessors have relatively large Level 1 instruction caches and large Level 1 data caches. Our microprocessors also contain on-chip Level 2 caches that improve performance by reducing the average time to access data from memory, and also help reduce power by decreasing the number of power-burning memory accesses to dynamic random access memory, or DRAM.
 
  •  LongRun Power Management. Our proprietary LongRun technology is enabled by the monitoring and optimization capabilities of Code Morphing software. LongRun monitors levels of user activity to determine how much performance is actually needed. Our chip has special purpose hardware that allows LongRun to rapidly adjust the frequency and voltage of the chip to a variety of levels to closely match the needed level of performance. Reducing frequency and voltage can substantially reduce the power consumed by our microprocessors, which in turn leads to longer battery life.
 
  •  Integrated Northbridge Chipset. Because we have moved many traditional chip functions from hardware into software, the basic processor requires a relatively small chip area. This provides the opportunity to integrate a full PCI bus controller, a synchronous DRAM, or SDRAM, memory interface, and, on some Crusoe microprocessors, a double data rate SDRAM, or DDR SDRAM, memory interface. A PCI bus connects a processor to user input/output devices such as a graphics controller or modem. These functions have been traditionally provided in a second chip, called a northbridge. Our microprocessors integrate this northbridge functionality onto the same silicon die as the processor. This increased level of integration reduces both power requirements and motherboard area, which are critical resources in small mobile devices.

      Our innovative software-based microprocessor technologies can enable computers engineered with our microprocessors to achieve a variety of benefits, including extended battery life, reduced heat dissipation, lighter weight, and competitive performance and full compatibility with x86 and Internet software.

      In support of our microprocessor development and business, we are also are engaged in the research, design, product development and system integration of many of the software and hardware technologies that make up a complete x86 PC compatible computer system. In addition to the microprocessor, the quality of the final computer system depends on the successful integration and optimization of all of the various hardware and software components in the computer. For example, we have developed tools, methodologies, techniques and related expertise in the development of basic input/output software, or BIOS, power management technologies for energy efficiency and battery life, and thermal management technologies to reduce heat dissipation. We have also invested substantial resources in developing tools, expertise and test environments for compatibility testing. We test compatibility across three major areas: x86 compatibility, hardware compatibility, and full operating system and application compatibility. Our understanding of the complete

4


Table of Contents

computer system and our ability to provide and improve an optimized total platform solution for our customers are the result of our core competencies and technologies.

      We also design and build, on a limited scale, PC-compatible computer systems based on our microprocessors. We build these systems for internal engineering use in order to test our microprocessors in a real system environment. We believe that the detailed design specifications are valuable to our customers as known working reference designs. By providing schematics, motherboard layout and extensive design notes, we can help our customers save time to market. We have a systems engineering department that develops and builds reference designs suitable for use in notebook computers and embedded systems. We also use these systems for many in-house purposes, such as testing new Code Morphing software, testing basic input/output systems, benchmarking and compatibility testing. We also take an active role in helping our customers debug and optimize the design of their platforms for battery life and performance.

Transmeta’s Strategy

      Our objective is to supply industry-leading energy efficient microprocessor solutions that deliver x86 software compatibility at a variety of compelling cost and performance points. Key elements of our strategy include:

      Extending Our Expertise in Software-Based Microprocessor Technologies. We plan to continue to extend our expertise in software-based microprocessor technology in order to develop and bring to market differentiated microprocessor products. We have and will continue to develop successive generations of hardware architectures and Code Morphing software optimizations to further enhance power management and performance, while maintaining x86 software compatibility. We also will continue to exploit the unique characteristics of software to continue to move additional functions from hardware into software, and to develop and implement new features, such as security. We plan to continuously extend the ability of our Code Morphing software to “learn” about the characteristics of an application program while it is running, and to use this knowledge to improve performance and reduce power consumption.

      Focusing on Mobile Computer Markets. Our initial goal has been to target our microprocessors at growing markets where energy efficiency, mobility and x86 PC software compatibility are paramount, such as in the mobile Internet computing market. We believe that mobile Internet computing devices are at the convergence point between communications and computing. Our current products are directed at the market for ultra-light mobile notebook computers, which typically weigh less than three pounds and feature extended battery life. We are also focused on evolving markets, where energy efficiency and low cost are important.

      Developing New Markets Beyond Mobile Computing. We also believe that there are new market opportunities for our microprocessors where energy efficiency and x86 software compatibility are particularly important, but where mobility and battery life may not be a factor. Next generation cable television set-top boxes, for example, will need x86 compatibility to provide Internet connectivity and web browsing, and sufficient performance to deliver streaming media in a home environment where a cool and quiet system without a noisy fan will be desired. Other emerging markets for which the energy efficiency advantages and software-based design of our products are particularly attractive include quiet desktop PCs, small office/home office servers and high-density blade servers.

      Collaborating with Other Companies that Enhance Our Business. We work closely with our OEM customers to collaborate on the specifications for our next generation products. We have continued to develop our working relationship with Microsoft in order both to ensure compatibility between our microprocessors and Microsoft’s software products and to collaborate on future products. We work with our foundry partner Taiwan Semiconductor Manufacturing Co., or TSMC, to fabricate silicon wafers using advanced manufacturing process technologies rather than developing our own manufacturing facilities. We additionally work with Advanced Semiconductor Engineering, or ASE, for substantially all of our assembly and test services.

      Developing and Sharing with Customers Our Systems Expertise. To speed the adoption of our technology and improve our customers’ time-to-market, we often provide potential customers with complete reference computer system solutions. By building an entire computer system, we can innovate across all the

5


Table of Contents

components of a computer system and help our customers resolve system design issues. We are committed to bringing expertise to our customers not only in microprocessors, but also in the engineering know-how of motherboard design, porting of basic input/output system software, operating system bring up, compatibility testing, power management tuning and thermal design issues. We believe that our ability to provide comprehensive systems expertise will continue to improve our customers’ time-to-market and accelerate the adoption of the Crusoe solution.

Products

      In January 2000, we announced our first family of microprocessor products under the brand name Crusoe. The Crusoe microprocessor family has evolved to include multiple models that feature different levels of performance and different cost structures. Our current products include the TM5400/ TM5600 generation and TM5500/ TM5800 generation Crusoe microprocessors, the Crusoe Special Embedded (SE) microprocessors, and our next generation TM8000 microprocessor expected to be commercially available during the third quarter of 2003.

      The TM5400 and TM5600 processors were manufactured prior to 2002 in a 0.18 micron CMOS technology. These microprocessors are similar except in the size of their level 2 cache. The TM5400 has a 256 KByte level 2 cache, and the TM5600 has a 512 KByte level 2 cache. Both processors have a 64 KByte level 1 data cache and 64 KByte level 1 instruction cache as well as an integrated “northbridge”, which consists of a PCI bus controller, a SDR DRAM controller, and a DDR DRAM controller. These processors feature maximum operating frequencies up to 667 MHz.

      The TM5500 and TM5800 processors are manufactured in a 0.13 micron CMOS technology. These microprocessors are similar except in the size of their level 2 cache. The TM5500 has a 256 KByte level 2 cache, and the TM5800 has a 512 KByte level 2 cache. Both processors have a 64 KByte level 1 data cache and 64 KByte level 1 instruction cache as well as an integrated “northbridge”, which consists of a PCI bus controller, a SDR DRAM controller, and a DDR DRAM controller. These processors currently feature maximum operating frequencies up to 1000 MHz. We introduced the TM5500/ TM5800 in June 2001 and began to derive product revenue from TM5500/ TM5800 sales during the fourth quarter of 2001.

      The Crusoe SE processors are x86 software compatible general purpose processors designed specifically for embedded applications. They are also manufactured in a 0.13 micron CMOS technology.

      The TM8000 processor, our next generation microprocessor product, was publicly demonstrated in November 2002. We publicly announced information about the TM8000 in February 2003. Our TM8000 processors will also be manufactured in a 0.13 micron CMOS technology. In addition to our legacy Code Morphing software and LongRun technologies, the TM8000 includes three new high performance bus interfaces. It has an on-chip 400 MHz HyperTransportTM bus interface, for increased input/output efficiency. The new processor also includes an on-chip Double Date Rate 400 (DDR-400) SDRAM memory interface, which will substantially increase throughput over earlier DDR-266 interfaces. The TM8000 also has an on-chip AGP-4X graphics interface for industry standard, high performance graphics solutions. All three of these new interfaces allow the TM8000 processor to achieve more work per clock, which results in greater energy efficiency and longer battery life for mobile computer users. The first TM8000 processors are expected to feature maximum operating frequencies up to 1200 MHz, and to be commercially available in the third quarter of 2003.

Customers

      We currently sell our products to many of the computing industry’s leaders who in turn produce cutting edge mobile computing solutions. Our customers include, among others, Sony Electronics, Fujitsu, Uniquest (acting as the distributor of our product for the Hewlett-Packard Tablet PC), Toshiba, NEC, Hitachi, Sharp, Casio and Siltrontech Electronics. Our server customers include RLX Technologies and NEC. Sony Electronics and Fujitsu accounted for 37% and 26%, respectively, of our net product revenue in fiscal 2002.

6


Table of Contents

Sales and Marketing

      We sell our products directly to OEMs and, to a lesser extent, through distributors, stocking representatives and manufacturers’ representatives. We have added manufacturers’ representatives and distributors in Europe, and manufacturers’ representatives in North America. Etron Corporation Ltd. is our manufacturers’ representative for Korea. Uniquest, Siltrontech Electronics and Edom Technology are our primary distributors in Hong Kong and Taiwan, and All American Semiconductor is our exclusive distributor in North America. Inno Micro Corporation and Shinden Hightex Corporation have been added as distributors for Japan. Our distributors are restricted from selling to certain OEMs and major notebook manufacturers and have provisions in their agreements specifying inventory levels, price protection policies and rights of return policies for non end-of-life products. As needed, we will continue to add representation to our current sales and distribution network.

      In addition, we have field applications engineers who work directly with our customers. We have opened offices in Taiwan and Japan to provide sales and customer support. We work with our potential customers to select, integrate and tune hardware and software system components that make up the final computer system. We also provide potential customers with reference platform designs, which we believe will enable our customers to achieve easier and faster transitions from the initial prototype designs through final production releases. We believe these reference platform designs also will enhance our targeted customers’ confidence that our products will meet their market requirements and product introduction schedules.

Manufacturing

      We use third-party manufacturers for wafer fabrication. By subcontracting our manufacturing, we focus our resources on product design and eliminate the high cost of owning and operating a semiconductor fabrication facility. This fabless business model also allows us to take advantage of the research and development efforts of manufacturers, and permits us to work with those manufacturers that offer the most advanced manufacturing processes and competitive prices.

      We currently use Taiwan Semiconductor Manufacturing Co., or TSMC, to fabricate wafers for our microprocessors. We place orders with TSMC on a purchase order basis. We do not have a manufacturing agreement with TSMC or a guaranteed level of production capacity or long term contractual wafer pricing with TSMC. TSMC may allocate capacity to other companies and reduce deliveries to us on short notice.

      Our designs are compatible with industry-standard CMOS manufacturing processes. Substantially all of our products are now fabricated using 0.13 micron process technologies. We continuously evaluate the benefits, on a product-by-product basis, of migrating to a smaller geometry process technology to reduce costs and increase the performance of our microprocessors. Difficulties in shifting to smaller geometry process technologies or new manufacturing processes have and may continue to lead to delays in product deliveries or may lead to reductions in manufacturing yields.

      We currently contract with Advance Semiconductor Engineering, or ASE, to perform the initial testing of the silicon wafers that contain our microprocessors. After initial testing, the silicon wafers are cut into individual semiconductors and assembled into packages. All testing is performed on standard test equipment using proprietary test programs developed by our test engineering group. We periodically inspect our test facilities to ensure that their procedures remain consistent with those required for the assembly of our products. We rely upon ASE to assemble and test substantially all of our products. This reliance on ASE could result in product shortages or delays in the future. If these shortages or delays were significant, our customers might seek alternative sources of supply, which could harm our operating results and reputation.

      We participate in quality and reliability monitoring through each stage of the production cycle by reviewing data from our wafer fabrication plants and assembly subcontractor. We closely monitor wafer fabrication plant production to enhance product quality and reliability and yield levels.

7


Table of Contents

Competition

      The market for microprocessors is intensely competitive, rapidly evolving and subject to rapid technological change. We believe that competition will become more intense in the future and may cause price reductions, reduced gross margins and loss of market share, any one of which could significantly reduce our future revenue and increase our losses. Significant competitors that offer microprocessors for the notebook computer market include Intel, Advanced Micro Devices and VIA Technologies. Intel currently manufactures lower power versions of its microprocessors targeting applications in the ultra-light notebook computer market.

      We compete on the basis of a variety of factors, including:

  •  technical innovation;
 
  •  performance of our products, including their power usage, product system compatibility, speed, reliability and density;
 
  •  product price;
 
  •  product availability;
 
  •  reputation and branding; and
 
  •  technical support.

      Many of our current and potential competitors have longer operating histories, significantly greater financial, technical, product development and marketing resources, greater name recognition and larger customer bases than we do. Many of our competitors also have significant influence in the industry. We may not be able to compete effectively against current and potential competitors, especially those with significantly greater resources and market leverage.

Intellectual Property

      Our success depends in part upon our ability to maintain the proprietary aspects of our technology and to operate without infringing the proprietary rights of others. We rely on a combination of patents, copyrights, trademarks, trade secret laws and contractual restrictions on disclosure to protect our intellectual property rights. Our current patents principally cover microprocessors, software, components for microprocessors and systems including microprocessors. It is possible that no patents will issue from additional patent applications that we have filed. Even if additional patents are issued, taken together with our existing patents, they may not provide sufficiently broad protection to protect our proprietary rights. We hold a number of trademarks, including Transmeta, Crusoe, LongRun and Code Morphing.

      Legal protections afford only limited protection for our technology. Despite our efforts to protect our proprietary rights, unauthorized parties may attempt to copy aspects of our products or to obtain and use information that we regard as proprietary. In addition, leading companies in the semiconductor industry have extensive intellectual property portfolios relating to semiconductor technology. From time to time, third parties, including these leading companies, may assert exclusive patent, copyright, trademark and other intellectual property rights to technologies and related methods that are important to us. We have received, and may in the future receive, communications from third parties asserting patent or other intellectual property rights covering our products. There are currently no such third party claims that we believe to be material. In the future, however, litigation may be necessary to defend against claims of infringement or invalidity, to determine the validity and scope of the proprietary rights of others, to enforce our intellectual property rights, or to protect our trade secrets.

Employees

      At December 31, 2002, we employed 289 people in the United States, Japan, Taiwan and Europe. Of these employees, 216 were engaged in research and development, 28 were engaged in sales and marketing and 45 were engaged in general and administrative functions. None of our employees is subject to any collective bargaining agreements. We believe that our employee relations are good.

8


Table of Contents

Available Information

      We make available free of charge on or through our Internet address located at www.transmeta.com our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file that material with, or furnish it to, the Securities and Exchange Commission.

 
Item 2.      Properties

      We lease a total of approximately 131,225 square feet of office space in four buildings in a business park complex located in Santa Clara, California. We lease space in these buildings under four separate leases all of which expire in June 2008. During fiscal 2002, we subleased approximately 8,280 square feet of office space in Santa Clara to a single subtenant. The sublease agreement expired in July 2002 and the subtenant vacated the subleased office space. We also lease approximately 5,000 square feet of office space in a two-story office building located in Acton, Massachusetts under a separate lease agreement, which expires in February 2004. We also lease office space in Taiwan, Japan and Europe to support our sales and marketing personnel worldwide. As a result of our workforce reduction completed in the third quarter of fiscal 2002, we vacated a total of approximately 72,730 square feet of office space in Santa Clara, California and Acton, Massachusetts as of September 30, 2002. We have listed the excess office space with a real estate broker in an effort to secure one or more subtenants, and in early fiscal 2003, we subleased 8,600 square feet of our vacant facilities. We believe the facilities we currently occupy are adequate to meet our needs for the foreseeable future.

 
Item 3.      Legal Proceedings

      Beginning in June 2001, Transmeta, its directors, and certain of its officers were named as defendants in several putative shareholder class actions filed in the United States District Court for the Northern District of California.(1) The Court consolidated those complaints into a single action entitled In re Transmeta Corporation Securities Litigation, Case No. C 01-02450 WHA. In December 2001, plaintiffs filed their consolidated amended complaint. The consolidated amended complaints purported to allege a class action on behalf of all persons, other than the individual defendants and the other officers of Transmeta, who purchased or acquired common stock of Transmeta during the period from November 7, 2000 to July 19, 2001. The consolidated amended complaints alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, and Sections 11 and 15 of the Securities Act of 1933, as amended. In March 2002, the Court granted in part and denied in part defendants’ motions to dismiss the consolidated amended complaint. In May 2002, the Court granted in part and denied in part defendants’ motion to dismiss the second amended complaint, and denied plaintiffs’ motion for leave to file a third amended complaint. In June 2002, defendants answered the second amended complaint as to the only surviving claim. In July 2002, defendants filed a motion for summary judgment relating to that claim. Plaintiffs moved for class certification, and the Court was scheduled to hear defendants’ motion for summary judgment and plaintiffs’ motion for class certification in December 2002. We believe that the allegations in the second amended complaint and the antecedent complaints are without merit and have defended the consolidated action vigorously. Notwithstanding this belief, and in order to avoid any additional waste of management time and expense, the Company and the individual defendants entered into an agreement with plaintiffs’ counsel to settle this action for approximately $5.5 million, all of which monies have been paid by


      1Hertzfeld, et al. v. Transmeta Corp., et al. (Case No. C-01-2450-JL, N.D. Cal.); Pond Equities v. Transmeta Corp., et al. (Case No. C-01-2463-JL, N.D. Cal.); McCarvill v. Transmeta Corp., et al. (Case No. C-01-2534-BZ, N.D. Cal.); Puente v. Transmeta Corp., et al. (Case No. C-01-2464-EDL, N.D. Cal.); Koroluk v. Transmeta Corp., et al. (Case No. C-01-2587-EDL, N.D. Cal.); Gammino v. Transmeta Corp., et al. (Case No. C-01-2614- EDL, N.D. Cal.); Dunnavant v. Transmeta Corp., et al. (Case No. C-01-20647-EDL, N.D. Cal.); LaFleur v. Transmeta Corp., et al. (Case No. C-01-03263 WHA, N.D. Cal.); Bernstein v. Transmeta Corp., et al. (Case No. C-01-03264 WHA, N.D. Cal.); and Shekleton v. Transmeta Corp., et al. (Case No. C-01-03291 WHA, N.D. Cal.).

9


Table of Contents

the defendants’ directors and officers (“D&O”) liability insurance. In December 2002, the court granted preliminary approval to the proposed settlement agreement. In March 2003, the Court granted final approval of the settlement agreement.

      Beginning in June 2001, the directors and certain officers of Transmeta were sued in four purported shareholder derivative actions.(2) In October 2001, those cases were consolidated in and by the Superior Court for Santa Clara County in a single action entitled In re Transmeta Corporation Derivative Litigation, Master File No. CV 799491. In April 2002, plaintiffs filed a consolidated amended complaint. Like its antecedents, the consolidated amended complaint is based upon the same general allegations set out in the purported shareholder class actions described above. In May and June 2002, Transmeta and the individual defendants filed two demurrers to the second amended complaint. In July 2002, the Court sustained Transmeta’s demurrer based on plaintiffs’ lack of standing, gave plaintiffs 90 days to file an amended complaint, and deferred consideration of the individual defendants’ demurrer as moot. We believe that the allegations in the second amended complaint and its antecedents are without merit and we have defended the action vigorously. Notwithstanding this belief, and in order to avoid any additional waste of management time and expense, the Company and the individual defendants agreed to settle this action for a sum of money to be paid entirely by defendants’ D&O liability insurance, similar to the proposed agreement to settle all of the claims in the federal class action. In December 2002, the parties executed a memorandum of understanding dated October 3, 2002 (the “MOU”). The MOU provides for a settlement of the consolidated derivative action pursuant to a definitive agreement and subject to judicial approval. The proposed settlement includes a dismissal with prejudice of all asserted claims, a release in favor of all defendants, and a payment to fees to counsel for the derivative plaintiffs in an amount to be approved by the Court but not to exceed $300,000. The court has scheduled a hearing on the proposed settlement for April 29, 2003.

      Beginning in June 2001, the Company, certain of its directors and officers, and certain of the underwriters for its initial public offering were named as defendants in three putative shareholder class actions filed in the United States District Court for the Southern District of New York. In January 2002, the Court ordered that all matters in the Southern District of New York be consolidated under In re Transmeta Corporation Initial Public Offering Securities Litigation, No. 01 CV 6492. On April 19, 2002, plaintiffs filed a consolidated amended complaint. The consolidated amended complaint alleges that the prospectus from Transmeta’s November 7, 2000 initial public offering failed to disclose certain alleged actions by the underwriters for the offering. The consolidated amended complaint alleges claims against Transmeta and several of its officers and directors under Sections 11 and 15 of the Securities Act of 1933, as amended, and under Sections 10(b) and Section 20(a) of the Securities Exchange Act of 1934, as amended. Other actions have been filed making similar allegations regarding the initial public offerings of more than 300 other companies. All of these consolidated cases have been coordinated for pretrial purposes as In re Initial Public Offering Securities Litigation, Master File No. 21 MC 92 (SAS). We believe that the allegations in the consolidated amended complaint and its antecedents are without merit and intend to defend the action vigorously. In November 2002, Transmeta joined a coordinated motion to dismiss filed on behalf of all issuers and individual defendants. In March 2003, the Court granted in part and denied in part that coordinated motion to dismiss, and issued an order regarding pleading of amended complaints.


      2Pereira v. David Ditzel, et al. (Case No. CV 799491), Sweeney v. Mark Allen, et al. (Case No. CV 799667), and Scotter v. David Ditzel, et al. (Case No. CV 808264), all filed in Superior Court for Santa Clara County, California, and Krim v. David R. Ditzel, et al. (Case No. CV 418524), filed in Superior Court for San Mateo County, California, and later transferred to Santa Clara County pursuant to stipulated consolidation order.

10


Table of Contents

 
Item 4.      Submission of Matters to a Vote of Security Holders

      Not applicable.

PART II

 
Item 5.      Market for Registrant’s Common Equity and Related Stockholder Matters

Market Information for Common Stock

      Transmeta’s common stock began trading on the Nasdaq National Market on November 6, 2000 under the symbol “TMTA”. The following table shows the high and low sale prices reported on the Nasdaq National Market for the periods indicated. The market price of our common stock has been volatile. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Risks That Could Affect Future Results.” On March 21, 2003, the closing price of our common stock was $1.24.

                   
High Low


Fiscal year ended December 31, 2002
               
 
First quarter
  $ 4.47     $ 2.15  
 
Second quarter
    3.87       1.79  
 
Third quarter
    2.34       0.85  
 
Fourth quarter
    1.64       0.74  
Fiscal year ended December 31, 2001
               
 
First quarter
  $ 37.25     $ 12.00  
 
Second quarter
    25.00       5.12  
 
Third quarter
    5.55       1.25  
 
Fourth quarter
    3.22       1.17  

Stockholders

      As of March 21, 2003, we had approximately 603 holders of record of our common stock. This does not include the number of persons whose stock is in nominee or “streetname” accounts through brokers.

Dividends

      Transmeta has never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business and do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future.

Securities Authorized For Issuance Under Equity Compensation Plans

      The information required by this item is incorporated by reference to the caption “Equity Compensation Plan Information” in our Proxy Statement for our May 2003 Annual Meeting.

Recent Sales of Unregistered Securities

      During the year ended December 31, 2002, we issued and sold the following unregistered securities:

      In February 2002, we issued 340,483 shares of common stock, valued at $1.0 million, to an intellectual property owner as partial consideration for certain intellectual property and related assets that we acquired in February 2001.

      The sales and issuance of securities listed above were determined to be exempt from registration under Section 4(2) of the Securities Act or Regulation D promulgated under the Securities Act as transactions by an issuer not involving a public offering.

11


Table of Contents

Use of Proceeds From Sales of Registered Securities

      Our Registration Statement on Form S-1 (File No. 333-44030) related to our initial public offering was declared effective by the Securities and Exchange Commission on November 6, 2000. A total of 14,950,000 shares of our common stock were registered with the Securities and Exchange Commission with an aggregate offering price of approximately $314 million. Net offering proceeds to us (after deducting underwriting discounts and offering expenses) were approximately $289.4 million.

      As of December 31, 2002, we paid $14.5 million of the net proceeds to IBM under the terms of our amended license agreement, approximately $13.2 million in property and equipment purchases and $20.5 million for the purchase of intellectual property and related assets from Seiko Epson and other intellectual property owners. We have also paid approximately $190.6 million to fund ordinary operating expenses. The remaining net proceeds have been invested in short-term interest bearing, investment-grade securities.

 
Item 6.      Selected Financial Data

      The following table reflects selected unaudited consolidated financial information for Transmeta for the past five fiscal years. We have prepared this information using the historical audited consolidated financial statements of Transmeta Corporation for the five years ended December 31, 2002.

      It is important that you read this selected historical financial data with the historical consolidated financial statements and related notes contained in this Report as well as the section of this Report titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These historical results are not necessarily indicative of results to be expected in any future period.

                                             
Year Ended December 31,

2002 2001 2000 1999 1998





(In thousands, except per share data)
Consolidated Statement of Operations Data:
                                       
Revenue:
                                       
 
Product
  $ 24,247     $ 35,590     $ 16,180     $ 76     $ 326  
 
License
                      5,000       28,000  
     
     
     
     
     
 
   
Total revenue
    24,247       35,590       16,180       5,076       28,326  
Cost of revenue(1)
    17,127       48,694       9,461       18       71  
     
     
     
     
     
 
Gross profit (loss)
    7,120       (13,104 )     6,719       5,058       28,255  
Operating expenses:
                                       
 
Research and development
    63,603       67,639       61,415       33,122       23,467  
 
Purchased in-process research and development
          13,600                    
 
Selling, general and administrative
    29,917       35,460       27,045       12,811       12,616  
 
Restructuring charges(2)
    14,726                          
 
Amortization of deferred charges, patents and patent rights
    11,392       17,556       10,416       218        
 
Impairment write-off of deferred charges(3)
          16,564                    
 
Stock compensation(4)
    1,809       20,954       13,056              
     
     
     
     
     
 
   
Total operating expenses
    121,447       171,773       111,932       46,151       36,083  
     
     
     
     
     
 
Operating loss
    (114,327 )     (184,877 )     (105,213 )     (41,093 )     (7,828 )
 
Interest and other income
    4,962       14,686       9,174       2,456       892  
 
Interest expense
    (601 )     (1,060 )     (1,666 )     (1,952 )     (1,154 )
     
     
     
     
     
 
Loss before income taxes
    (109,966 )     (171,251 )     (97,705 )     (40,589 )     (8,090 )
 
Provision for income taxes
                      500       2,000  
     
     
     
     
     
 
Net loss
  $ (109,966 )   $ (171,251 )   $ (97,705 )   $ (41,089 )   $ (10,090 )
     
     
     
     
     
 
Net loss per share — basic and diluted
  $ (0.82 )   $ (1.33 )   $ (2.18 )   $ (1.51 )   $ (0.44 )
     
     
     
     
     
 
Weighted average shares outstanding — basic and diluted
    134,719       129,002       44,741       27,236       23,074  
     
     
     
     
     
 

12


Table of Contents

                                         
December 31,

2002 2001 2000 1999 1998





(In thousands)
Consolidated Balance Sheet Data:
                                       
Cash and cash equivalents
  $ 16,613     $ 57,747     $ 259,744     $ 46,645     $ 27,809  
Short-term investments
    112,837       183,941       83,358       19,799        
Working capital
    116,033       217,152       343,004       58,912       21,909  
Total assets
    197,555       309,024       412,536       99,443       43,497  
Long-term obligations, net of current portion
    18,116       29,295       20,950       27,020       10,798  
Total stockholders’ equity
    140,847       244,965       364,916       63,083       24,032  


(1)  Cost of revenue includes a charge of $28.1 million related to an inventory charge taken in the second quarter of 2001, which was partially offset by the sale of such previously written off inventory and reversal of previously accrued inventory charges of $1.9 million and $2.5 million in fiscal 2002 and 2001, respectively.
 
(2)  Restructuring charges primarily includes $8.9 million for excess facilities, $1.6 million for property and equipment and prepaid software maintenance write-offs and $4.1 million related to a reduction in workforce.
 
(3)  During the fourth quarter of 2001, we wrote-off $16.6 million of long-lived asset balances related to deferred charges under licensing agreements.
 
(4)  Stock compensation in fiscal 2001 includes variable stock compensation charges of $2.5 million, $16.6 million of deferred stock compensation as a result of options granted prior to November 2000 and $1.7 million in forgiveness of interest on notes receivables associated with option exercises.

 
Item 7.      Management’s Discussion and Analysis of Financial Condition and Results of Operations

      NOTE: For a more complete understanding of our financial condition and results of operations, and some of the risks that could affect future results, see “Risks That Could Affect Future Results.” This section should also be read in conjunction with the Consolidated Financial Statements and related Notes, which immediately follow this section.

Overview

      We develop and sell software-based microprocessors and develop additional hardware, software, and system technologies that enable manufacturers to build highly efficient computing systems characterized by low power consumption, reduced heat dissipation and the high performance required to run standard x86 compatible programs. We originally developed our family of Crusoe microprocessors for lightweight notebook computers and other mobile computing devices, but we have developed and are continuing to develop microprocessors suitable for a variety of existing and emerging end markets in which energy and thermal efficiency along with x86 software compatibility are desirable. We rely on independent, third party contractors to perform manufacturing, assembly and test functions. Our fabless approach allows us to focus on designing, developing and marketing our products and to significantly reduce the amount of capital needed to invest in manufacturing infrastructure.

      From our inception in March 1995 through January 2000, we were engaged primarily in research and development. In 1999, we began focusing on achieving design wins with original equipment manufacturers, or OEMs, in addition to our ongoing development activities. In January 2000, we introduced our Crusoe family of microprocessors and began recognizing product revenue from sales of these microprocessors in the first half of 2000. Through June 30, 2000, product shipments consisted of development systems and prototypes. We expect to be dependent on sales of Crusoe microprocessors and successive generations of these products for the foreseeable future.

      We sell our products directly to OEMs and, to a lesser extent, through distributors, stocking representatives and manufacturers’ representatives. We have added manufacturers’ representatives and distributors in

13


Table of Contents

Europe, and manufacturers’ representatives in North America. Etron Corporation Ltd. is our manufacturers’ representative for Korea. Uniquest, Siltrontech Electronics and Edom Technology are our primary distributors in Hong Kong and Taiwan, and All American Semiconductor is our exclusive distributor in North America. Inno Micro Corporation and Shinden Hightex Corporation have been added as distributors for Japan. Our distributors are restricted from selling to certain OEMs and major notebook manufacturers and have provisions in their agreements specifying inventory levels, price protection policies and rights of return policies for non end-of-life products. As needed, we will continue to add representation to our current sales and distribution network.

      The majority of our sales have been to a limited number of customers and sales are highly concentrated. Additionally, we derive a significant portion of our revenue from customers located in Asia. Sales to two customers, each of which is located in Japan, accounted for 37% and 26%, respectively, of our net product revenue in fiscal 2002. The same two customers accounted for 30% and 12%, respectively, of our net product revenue in fiscal 2001 and 60% and 28%, respectively, of our net product revenue in fiscal 2000. Sales to two additional customers, each of which is located in Japan, accounted for 18% and 11%, respectively, of our net product revenue in fiscal 2001. The loss of a major customer, or the delay of significant orders from these customers could reduce or delay our recognition of revenue. Three customers accounted for 78% of our accounts receivable balance as of December 31, 2002, and four different customers accounted for 92% of our accounts receivable balance as of December 31, 2001.

      All of our product sales to date have been denominated in U.S. dollars and we expect that most of our sales in the future will be denominated in U.S. dollars. We have not engaged in any foreign currency hedging activities, although we may do so in the future. Our product sales in 2002, 2001 and 2000 were primarily made to the notebook computer market. If our Crusoe products fail to achieve widespread acceptance in the notebook computer market we may not achieve revenue sufficient to sustain our business.

      Cost of revenue consists primarily of the costs of manufacturing, assembly and test of our silicon chips, and compensation and associated costs related to manufacturing support, logistics and quality assurance personnel. Gross margin is the percentage derived from dividing gross profit by revenue. Our gross margin each quarter is affected by a number of factors, including competitive pricing, mix, foundry pricing, yields, production flow costs and speed distribution of our products. Research and development expenses consist primarily of salaries and related overhead costs associated with employees engaged in research, design and development activities, as well as the cost of masks, wafers and other materials and related test services and equipment used in the development process. Selling, general and administrative expenses consist of salaries and related overhead costs for sales, marketing and administrative personnel and legal and accounting services.

      We previously recorded deferred stock compensation representing the difference between the deemed fair value of our common stock at the date of grant for accounting purposes and the exercise price of these options. Deferred stock compensation is presented as a reduction of stockholders’ equity and is amortized on the graded vesting method. As of December 31, 2002, approximately $3.0 million was recorded on our balance sheet, which will be amortized through 2004 using an accelerated graded method.

      Historically we have incurred significant losses. As of December 31, 2002, we had an accumulated deficit of $454.9 million. We expect to incur substantial losses for the foreseeable future. We also expect to incur significant research and development and selling, general and administrative expenses. As a result, if our revenue does not increase substantially, our operating results will be adversely affected, and we will not achieve profitability. During the fourth quarter of fiscal 2001 and into the first quarter of fiscal 2002 our revenue was primarily impacted by production difficulties. Additionally, beginning in the second quarter of fiscal 2001 and continuing through the fourth quarter of fiscal 2002 our net product revenues have been adversely affected by the slow worldwide and particularly, Japanese economies. If we experience additional production constraints or if economic conditions do not improve, or worsen, we would continue to experience adverse impacts on our revenue and operating results.

      For ease of presentation, the accompanying financial information has been shown as of December 31 and calendar quarter ends for all annual and quarterly financial statement captions. Fiscal years 2002, 2001 and 2000 each consisted of 52 weeks and ended on December 27, December 28 and December 29, respectively.

14


Table of Contents

Critical Accounting Policies

      We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the consolidated financial statements:

  •  Estimation of inventory valuations;
 
  •  Valuation of long-lived and intangible assets;
 
  •  Restructuring charges; and
 
  •  Revenue reserves.

      Estimation of Inventory Valuations. In accordance with several accounting pronouncements, including Accounting Research Bulletin 43, our inventory valuation policy stipulates that at the end of each reporting period we write-down or write-off our inventory for estimated obsolescence or unmarketable inventory. The amount of the write-down or write-off is equal to the difference between the cost of the inventory and the estimated market value of the inventory based upon reasonable assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs or write-offs may be required. Additionally, as we introduce product enhancements and new products, and improve our manufacturing processes, demand for our existing products in inventory may decrease. Inventory on hand in excess of forecasted demand, which is generally twelve months or less, is not valued. At the end of the second quarter of 2001, consistent with this policy, we recorded a charge of $28.1 million primarily to write-off certain older inventory products as a result of an actual decrease of future demand for these older products. In the future, we may find that similar assessments may warrant another significant write-down or write-off of inventory.

      Valuation of Long-Lived and Intangible Assets. Our accounting policy related to the valuation and impairment of long-lived assets is in accordance with the Financial Accounting Standards Board’s (FASB) Statement of Financial Accounting Standards (SFAS) 144, Accounting for the Impairment or Disposal of Long-Lived Assets. In accordance with our policy, at the end of each accounting period we evaluate our long-lived and intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of long-lived assets may not be recoverable. Recoverability of assets to be held and used is determined by comparing the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds the future undiscounted cash flows the asset is considered to be impaired and the impairment charge recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the fourth quarter of 2001, consistent with this policy, we recorded an impairment write-off charge of $16.6 million related to deferred charges under certain license agreements with IBM and Toshiba. Although we do not now believe that our existing long-lived assets will be impaired in the future, we continue to periodically evaluate our long-lived assets for impairment in accordance with SFAS 144 and acknowledge it is at least reasonably possible that such evaluation might result in future adjustments for impairment. Such an impairment might adversely affect our operating results.

      Restructuring Charges. In fiscal 2002, in accordance with EITF Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)”, we accrued for restructuring costs when we made a commitment to a firm exit plan that specifically identified all significant actions to be taken in conjunction with our response to a change in our strategic plan, product demand, increased costs or other environmental factors. Our assumptions used in determining the estimation of restructuring expenses include the determination of the period that it will take to sublet our vacated premises, the market price that we will be able to command for the subleased space and the discounted interest rate that we are using to determine the present value of our future lease obligations. Any significant variation in these estimates compared to actual results may have a material impact on our restructuring expenses and our operating results. We reassess the prior restructuring accruals on a quarterly basis to reflect changes in the costs of the restructuring activities, and we record new restructuring accruals as commitments are incurred. During the second quarter of fiscal 2002, we recorded restructuring charges of $10.6 million primarily related to lease costs and equipment write-offs. We recorded restructuring charges of

15


Table of Contents

$4.1 million related to a reduction in workforce during the third quarter of fiscal 2002. Any future restructuring costs, if any, would be recorded in accordance with Statement of Financial Accounting Standards No. 146 “Accounting for Costs Associated with Exit or Disposal Activities” (SFAS 146), which requires that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred. SFAS 146 is effective for exit or disposal activities that are initiated after December 31, 2002.

      Revenue Reserves. We record a provision for estimated sales returns and allowances on product sales in the same period as the related revenues are recorded. We base these estimates on actual historical sales returns, allowances and other known factors. Actual returns and allowances could be different from our estimates and current provisions, resulting in future adjustments to our operating results.

Results of Operations

 
Revenue

      Fiscal 2002 Compared to Fiscal 2001. Total net product revenue for fiscal 2002 was $24.2 million, compared to $35.6 million in fiscal 2001. The decrease of $11.4 million is due to several factors, including production difficulties at the beginning of fiscal 2002, decreases in average selling prices during fiscal 2002, as well as unfavorable global economic conditions and reduced information technology spending, particularly in Japan. During fiscal 2002 and 2001, demand for our products continued to depend primarily on sales by our OEM customers of notebook computers that incorporate our products.

      Fiscal 2001 Compared to Fiscal 2000. Total net product revenue for fiscal 2001 was $35.6 million, compared to $16.2 million in fiscal 2000. The increase of $19.4 million is a result of a full year of volume shipments of products during 2001 compared to volume shipments in the last two quarters of fiscal 2000.

 
Gross Margin

      Fiscal 2002 Compared to Fiscal 2001. For fiscal 2002, gross margin was 29.4%, compared to (36.8)% for fiscal 2001. Gross margin for fiscal 2001 included an inventory charge of $28.1 million to cost of revenue in the second quarter primarily related to the write-off of excess inventory. In fiscal 2002 and 2001, we recognized 100% gross profit of $0.7 million and $1.7 million, respectively, related to the sale of previously written-off inventory. In fiscal 2002 and 2001, we recognized 100% gross profit of $1.2 million and $0.8 million, respectively, related to the reversal of previously accrued inventory related purchase commitments due to favorable settlements of such purchase commitments.

      Fiscal 2001 Compared to Fiscal 2000. For fiscal 2001, gross margin was (36.8)%, compared to 41.5% in 2000. Gross margin for fiscal 2001 included an inventory charge of $28.1 million to cost of revenue in the second quarter of fiscal 2001 primarily related to the write-off of excess inventory. Inventory purchases and commitments are based upon product demand forecasts. We built inventory levels for certain components with long lead times and entered into commitments for certain components. Due to a sudden and significant decrease in demand for our products in fiscal 2001, inventory levels and purchase commitments exceeded our estimated requirements based on demand forecasts. We believe the decrease in demand was primarily due to unfavorable economic conditions and reduced information technology spending, particularly in Japan. The inventory charge was calculated based on inventory levels in excess of forecasted demand for each specific product. Subsequently, we recognized 100% gross profit of $1.7 million in fiscal 2001 related to the sale of previously written-off inventory and $0.8 million related to the reversal of previously accrued inventory related purchase commitments due to favorable settlements of such purchase commitments. During each of the third, and particularly the fourth quarters of 2001, our gross margin also decreased due in part to lower than expected product revenue, which did not allow for adequate overhead absorption and the scrapping of older inventory.

 
Research and Development

      Fiscal 2002 Compared to Fiscal 2001. Research and development expenses were $63.6 million in fiscal 2002 compared to $67.6 million in fiscal 2001. The decrease is primarily due to lower employee compensation

16


Table of Contents

and benefit costs and consultant fees related to our reduction in workforce in the third quarter of fiscal 2002. Additionally, depreciation expense decreased in fiscal 2002 as a result of the write-off of certain fixed assets related to our restructuring activities in the second quarter of fiscal 2002. These decreases were partially offset by an increase in prototype expenditures related to updates of our existing microprocessors, as well as next-generation microprocessors.

      Fiscal 2001 Compared to Fiscal 2000. Research and development expenses were $67.6 million in fiscal 2001, compared to $61.4 million in fiscal 2000. The increase is primarily due to increased employee compensation and benefit costs and consultant fees, as well as increased software maintenance costs associated with product development. These increases were partially offset by a decrease in prototype expenditures compared to fiscal 2000.

 
Purchased In-Process Research and Development

      In April 2001, we licensed certain computing technologies and intellectual property from Advanced Micro Devices, Inc. (AMD), including AMD’s HyperTransport interconnect technology for our future products and technology initiatives. As initial consideration for the patents and patent rights licensed under the agreement, we issued 1,000,000 unregistered shares of our common stock valued at $15.0 million based upon the average closing price of our stock prior to issuance. For accounting purposes, however, the value of the shares was determined using the closing price of the stock at the date of issuance, or $13.60, resulting in a recorded value of $13.6 million. The entire $13.6 million was expensed as purchased in-process research and development during the second quarter of 2001 because the HyperTransport technology is designed for use in products that are currently in research and development.

 
Selling, General and Administrative

      Fiscal 2002 Compared to Fiscal 2001. Selling, general and administrative expenses were $29.9 million in fiscal 2002, compared to $35.5 million in fiscal 2001. The decrease is primarily due to lower employee compensation and benefit costs and consultant fees related to our reduction in workforce in the third quarter of fiscal 2002. Additionally, our efforts to reduce overall operating expenses resulted in decreases in travel, trade show and advertising costs during the third and fourth quarters of fiscal 2002. These decreases were partially offset by increases in our insurance renewal premiums for our various corporate insurance policies.

      Fiscal 2001 Compared to Fiscal 2000. Selling, general and administrative expenses were $35.5 million in fiscal 2001, compared to $27.0 million in fiscal 2000. The increase was primarily due to increased employee compensation and benefit costs, consultant fees and recruiting costs.

 
Restructuring Charges

      During fiscal 2002, we recorded restructuring charges of $14.7 million. We recorded charges of $10.6 million in the second quarter of fiscal 2002 consisting primarily of lease costs, equipment write-offs and other costs as we identified a number of leased facilities and leased equipment that were no longer required. We recorded severance and termination charges of $4.1 million in the third quarter of fiscal 2002 related to the reduction in workforce. Approximately 195 employees and contractors were terminated on July 18, 2002. Other than future lease payments for our vacated facilities, the majority of our restructuring activities have been completed. We evaluated the restructuring reserve balance as of December 31, 2002 and determined no adjustments were needed.

 
Amortization of Deferred Charges, Patents and Patent Rights

      Amortization charges for fiscal 2002 and fiscal 2001 relate to various patents and patent rights acquired from Seiko Epson and others during fiscal 2001. Amortization charges for fiscal 2001 and fiscal 2000 also include charges related to our IBM and Toshiba technology license agreements, as amended, which were originally entered into during fiscal 1997 and 1998, respectively. See Note 4 and Note 5 in the “Notes to Consolidated Financial Statements” for further discussion of our technology license agreements and patents and patent rights.

17


Table of Contents

      Fiscal 2002 Compared to Fiscal 2001. We recorded amortization charges of $11.4 million, compared to $17.6 million in fiscal 2001. The decrease is due to the impairment charge recorded during the fourth quarter of fiscal 2001 to adjust the IBM and Toshiba license agreements to their respective fair values, resulting in no additional amortization expenses being recorded in fiscal 2002 related to these deferred charges.

      Fiscal 2001 Compared to Fiscal 2000. We recorded amortization charges of $17.6 million in fiscal 2001, compared to $10.4 million in fiscal 2000. The increase is due to the capitalization and subsequent amortization related to the patents acquired from Seiko Epson and others in fiscal 2001.

 
Impairment Write-off of Deferred Charges

      Deferred charges related to IBM and Toshiba technology license agreements were being amortized on a straight-line basis through December 2003, which was the remaining license term during which the reacquired rights were originally in effect. See Note 4 in the “Notes to Consolidated Financial Statements” for further discussion of our technology license agreements. During the fourth quarter of 2001, due to the emergence of indicators of impairment, we performed an assessment of the carrying value our long-lived assets to be held and used. The assessment was performed in connection with our internal policies and pursuant to SFAS 121 “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of” because of the significant negative industry and economic trends affecting both our current operations and expected future operating cash flows. The conclusion of that assessment was that the anticipated future undiscounted cash flows was less than the carrying value for all long-lived assets, including the deferred charges. As a result, during the fourth quarter of 2001, we recorded a charge of $16.6 million to reduce the carrying amount of the deferred charges under license agreements based on the amount by which the carrying amount of these assets exceeded their fair value. Although these assets were impaired and written off, the associated remaining payments due to IBM of $23.0 million are still required and will continue to accrete interest until the final payment is made.

 
Stock Compensation

      Fiscal 2002 Compared to Fiscal 2001. Amortization of deferred stock compensation associated with options granted prior to November 2000, net of cancellation, was $3.6 million in fiscal 2002, compared to $16.6 million in 2001. The decrease is primarily a result of amortizing the deferred charge on an accelerated graded method, as well as a credit recorded to stock compensation expense of $1.7 million in the third quarter of fiscal 2002 related to our workforce reduction. The total credit to deferred compensation expense for cancellations was $3.4 million and $3.1 million for fiscal 2002 and 2001, respectively. In connection with stock options grants through November 2000, we expect to record $2.6 million in 2003 and $0.4 million in 2004.

      We apply variable accounting for certain stock option grants, which is included in deferred stock compensation, because during the fourth quarter of fiscal 2001, we did not enforce the recourse provisions of certain employee notes associated with option exercises. Therefore, we account for all outstanding notes as if they had terms equivalent to non-recourse notes, even though the terms of these notes were not in fact changed from recourse to non-recourse. As a result, we have and will continue to record variable stock compensation expense on the associated stock awards until the notes are paid. This variable stock compensation charge is based on the excess, if any, of the current market price of our stock as of period-end over the purchase price of the stock award, adjusted for vesting and prior stock compensation expense recognized on the stock award. Stock compensation for fiscal 2002 included a credit of $1.8 million recorded to stock compensation expense due to a lower market price of our stock at the end of fiscal 2002 compared the end of fiscal 2001. Stock compensation expense in fiscal 2001 included $2.5 million in variable stock compensation and $1.7 million in forgiveness of interest related to officer resignations.

      In the future, if the price of our stock increases $1 per share it will result in approximately $1.5 million of additional stock compensation expense, or if the stock price decreases $1 per share it will result in a benefit (reduction) in stock compensation expense of approximately the same amount. Because variable stock compensation expense is calculated based on the current market value of our common stock at the end of each accounting period, future stock compensation expense for these variable stock awards could increase

18


Table of Contents

significantly in periods when our stock price rises, and could reverse and become a benefit in periods when our stock price falls.

      Fiscal 2001 Compared to Fiscal 2000. Deferred stock compensation expense, net of cancellation, was $16.6 million in fiscal 2001, compared to $13.1 million in fiscal 2000. Additionally, stock compensation expense in fiscal 2001 included 2.5 million in variable stock compensation and $1.7 million in forgiveness of interest related to officer resignations, compared to zero in fiscal 2000. The increase is a result of a full year of amortization of the total deferred stock compensation expense of $46.0 million recorded in connection with our initial public offering in November 2000. The total credit to deferred compensation expense for cancellations was $3.1 million for fiscal 2001.

 
Interest and Other Income and Interest Expense

      Fiscal 2002 Compared to Fiscal 2001. Interest and other income was $5.0 million in fiscal 2002, compared to $14.7 million in fiscal 2001. The decrease is due to a decrease in the average invested cash balances during 2002 as we continue to use cash to fund operations, as well as a significant decrease in interest rates earned on investments during the period. As we continue to use cash to fund operations, our investment balances will decrease and as a result our interest income is expected to decrease over time. Interest expense was $0.6 million in fiscal 2002, compared to $1.1 million in fiscal 2001. The decrease year over year is the result of lower average debt balances due to several lease-financing arrangements expiring during 2002.

      Fiscal 2001 Compared to Fiscal 2000. Interest and other income was $14.7 million in fiscal 2001, compared to $9.2 million in fiscal 2000. The increase year over year is primarily due to larger average invested cash balances resulting from the closing of an equity offering in April 2000 and our initial public offering in November 2000. Interest expense was $1.1 million in fiscal 2001, compared to $1.7 million in fiscal 2000. The decrease year over year is due to lower average debt balances due to several lease-financing arrangements expiring during 2001.

Liquidity and Capital Resources

      Since our inception, we have financed our operations primarily through sales of equity securities and, to a lesser extent, from product revenue and lease financing. At December 31, 2002, we had $129.5 million in cash, cash equivalents and short-term investments compared to $241.7 million at December 31, 2001.

      Net cash used in operating activities was $93.9 million for the year ended December 31, 2002. This was primarily the result of the net loss of $110.0 million, as well as increases in inventories of $9.5 million and accounts receivable of $2.4 million, and a decrease in accounts payable and accrued liabilities of $3.4 million. The net loss and changes in operating assets and liabilities were partially offset by non-cash charges related to amortization of patents and patent rights of $11.4 million, $6.1 million of depreciation and amortization, $1.8 million in amortization of deferred compensation and $1.6 million of non cash restructuring charges. The net loss was further offset by a decrease in prepaid expenses and other current assets of $2.3 million.

      Net cash provided by investing activities was $49.7 million for the year ended December 31, 2002, and consisted primarily of $70.5 million net proceeds from the maturity of available-for-sale investments. These proceeds were partially offset by the $15.0 million partial settlement of long-term payable obligations for licensing agreements and patents and patent rights, as well as purchases of property and equipment of $5.6 million in fiscal 2002.

      Net cash provided by financing activities was $3.1 million for the year ended December 31, 2002, and consisted primarily of net proceeds from option exercises and employee stock purchase plan purchases of $4.6 million and proceeds from capital lease obligations of $1.1 million, partially offset by repayment of debt and capital leases obligations of $2.7 million.

      At December 31, 2002, we had $16.6 million in cash and cash equivalents and $112.8 million in short-term investments. We lease our facilities under non-cancelable operating leases expiring in 2008, and we lease

19


Table of Contents

equipment and software under non-cancelable leases with terms ranging from 36 to 48 months. At December 31, 2002, we had the following contractual obligations:
                                 
Payments Due by Period

Contractual Obligations Total Less Than 1 Year 1-3 Years After 4 Years





(In thousands)
Debt Obligations
  $ 31     $ 31              
Capital Lease Obligations
  $ 1,630     $ 888     $ 742        
Operating Leases
  $ 24,475     $ 4,216     $ 13,178     $ 7,081  
Unconditional Purchase Obligations
  $ 2,000     $ 2,000              
Other Long Term Obligations
  $ 39,500     $ 16,000     $ 23,500        

      We believe that existing cash and cash equivalents and short-term investments balances will be sufficient to fund our operations for the next twelve months. After this period, capital requirements will depend on many factors, including general economic conditions, the rate of sales growth, market acceptance of our products, costs of securing access to adequate manufacturing capacity, the timing and extent of research and development projects, increases in our operating expenses, and ultimately our ability to generate profits from operations. To the extent that existing cash and cash equivalents and short-term investments balances and any cash from operations are insufficient to fund our future activities, we may need to raise additional funds through public or private equity or debt financing. Although we are currently not a party to any agreement or letter of intent with respect to a potential acquisition or business combination, we may enter into acquisitions or business combinations in the future, which also could require us to seek additional equity or debt financing. Additional funds may not be available on terms favorable to us or at all.

Recent Accounting Pronouncements

      In July 2002, the FASB issued SFAS 146 “Accounting for Costs Associated with Exit or Disposal Activities”, which addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies EITF Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)”. The principal difference between SFAS 146 and EITF 94-3 relates to the timing of the recognition of a liability for a cost associated with an exit or disposal activity. SFAS 146 requires that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred. A liability for an exit cost as generally defined in EITF 94-3 is to be recognized at the date of an entity’s commitment to an exit plan. SFAS 146 is effective for exit or disposal activities that are initiated after December 31, 2002. We accounted for our restructuring activity during fiscal 2002 under EITF 94-3. We do not expect the adoption of SFAS 146 to have a material impact on our financial position or results of operations.

      In November 2002, the FASB issued FASB Interpretation No. 45 (FIN 45), “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantee’s of Indebtedness of Others.” FIN 45 requires that upon issuance of a guarantee, a guarantor must recognize a liability for the fair value of an obligation assumed under a guarantee. FIN 45 also requires additional disclosures by a guarantor in its interim and annual financial statements about the obligations associated with guarantees issued. The recognition provisions of FIN 45 are effective for any guarantees issued or modified after December 31, 2002. The disclosure requirements are effective for financial statements of interim or annual periods ending after December 15, 2002. Our adoption of FIN 45 did not have a material impact on our financial position or results of operations.

      In December 2002, the FASB issued SFAS 148 “Accounting for Stock-Based Compensation — Transition and Disclosure”, which amends SFAS 123 “Accounting for Stock-Based Compensation” and provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS 148 amends the disclosure requirements of SFAS 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reporting results. The transition guidance and annual disclosures provisions of SFAS 148 are effective for fiscal years ending

20


Table of Contents

after December 15, 2002. The interim disclosure provisions are effective for financial reports containing financial statements for interim periods beginning after December 15, 2002. We adopted the disclosure provisions of SFAS 148 for this Form 10-K. We will continue to account for stock-based compensation under the provisions of APB 25 “Accounting for Stock Issued to Employees” using the “intrinsic value” method. Accordingly, the adoption of SFAS 148 is not anticipated to have a material effect on our financial position, results of operations, or cash flows.

      In January 2003, the FASB issued FIN No. 46 “Consolidation of Variable Interest Entities.” FIN 46 requires a variable interest to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity’s activities or entitled to a receive a majority of the entity’s residual returns or both. A variable interest entity is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A variable interest entity often holds financial assets, including loans or receivables, real estate or other property. A variable interest entity may be essentially passive or it may engage in research and development or other activities on behalf of another company. The consolidation requirements of FIN 46 apply immediately to variable interest entities created after January 31, 2003. The consolidation requirements apply to older entities in the first fiscal year or interim period beginning after June 15, 2003. Certain of the disclosure requirements apply to all financial statements issued after January 31, 2003, regardless of when the variable interest entity was established. We do not expect that the adoption of this standard will have a material impact on our financial position or results of operations.

Risks that Could Affect Future Results

      The factors discussed below are cautionary statements that identify important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements in this Form 10-K. If any of the following risks actually occurs, our business, financial condition and results of operations would suffer. In this case, the trading price of our common stock could decline and investors might lose all or part of their investment in our common stock.

 
We Have a History of Losses, Expect to Incur Further Significant Losses and May Never Achieve or Maintain Profitability.

      We have a history of substantial losses and expect to incur further significant losses. We incurred net losses of $110.0 million in 2002, $171.3 million in 2001 and $97.7 million in 2000. As of December 31, 2002, we had an accumulated deficit of $454.9 million. Historically, we have increased our research and development, sales and marketing, and administrative expenses over time. Although we have recently taken steps to reduce operating expenses, we cannot assure you that our operating expenses will not increase in future periods. We also expect to incur substantial non-cash charges relating to the amortization of deferred charges, patents and patent rights and deferred stock and variable stock compensation, which will serve to increase our net losses further. Our revenue must increase if we are to achieve profitability under our current business model. We cannot assure you that our revenue will increase, so we may never achieve profitability. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or an annual basis.

 
Our Business Is Difficult to Forecast Because We Recognized Our First Product Revenue in the First Half of 2000.

      We introduced our first Crusoe microprocessors in January 2000 and recognized our first product revenue from these products in the first half of 2000. Through June 30, 2000, we had manufactured only limited quantities of our products. In September 2000, we began volume shipments. Thus, we have only a very limited operating history with our products. This limited history makes it difficult to forecast our business. Until 2000, we derived substantially all of our revenue from license fees, but we do not expect any significant license fee revenue in the foreseeable future. We need to generate substantial future revenue from product sales, but our ability to manufacture our products in production quantities and the revenue and income potential of our

21


Table of Contents

products and business are unproven. You should consider our chances of financial and operational success in light of the risks, uncertainties, expenses, delays and difficulties associated with new businesses in highly competitive technology fields, many of which may be beyond our control. If we fail to address these risks, uncertainties, expenses, delays and difficulties, the value of an investment in our common stock would decline further.
 
We Depend Upon Increasing Demand for Our Crusoe Microprocessors.

      We expect to derive virtually all of our revenue for the foreseeable future from the sale of our Crusoe microprocessors, which we only began to ship in volume in September 2000. Since September 2000 we have recognized substantially all of our revenue from sales of our Crusoe microprocessors. Therefore, our future operating results will depend on the demand for Crusoe products by existing and future customers. If our Crusoe microprocessors are not widely accepted by the market due to performance, price, compatibility or any other reason, or if, following acceptance, we fail to enhance our Crusoe products in a timely manner, demand for our products may fail to increase, or may diminish. If demand for our Crusoe products does not increase, our revenue will not increase and the value of an investment in our common stock would likely decline further.

 
We Are Subject to General Economic and Market Conditions.

      Our business is subject to the effects of general economic conditions in the United States and worldwide, and, in particular, market conditions in the semiconductor and notebook computer industries. In fiscal 2001 and 2002, our operating results were adversely affected by unfavorable global economic conditions and reduced information technology spending, particularly in Japan, where we currently generate the majority of our revenue. These adverse conditions resulted in decreased demand for notebook computers and, as a result, our products, which are components of notebook computers. Further, demand for our products decreases as computer manufacturers seek to manage their component and finished product inventory levels. If the economic conditions in Japan and worldwide do not improve, or worsen, we may continue to experience material adverse effects on our business, operating results, and financial condition.

 
If We Experience Continued Difficulties in Transitioning to New Manufacturing Technologies, We Could Experience Reduced Manufacturing Yields, Delays in Product Deliveries and Increased Expenses.

      Transitioning to new manufacturing technologies involves extensive redesigning of products and modifying the manufacturing processes for the products. Difficulties in shifting to smaller geometry process technologies and other new manufacturing processes have led to delays in product deliveries and increased expenses. In particular, during the third and fourth quarters of fiscal 2001 and to a lesser extent the first quarter of fiscal 2002, we experienced difficulties in bringing our products into volume production and distribution. As a result, in part, of these delays, our net product revenue in 2001 declined from $10.5 million in the second quarter to $5.0 million in the third quarter and then to $1.5 million in the fourth quarter. In addition, if we experience continued delays in product deliveries, our target customers could design a competitor’s microprocessor into their product, which would lead to lost sales and impede our ability to increase our revenue. Further, problems associated with manufacturing processes divert engineering personnel from product development and other tasks.

 
Our Future Revenue Depends Upon Our Ability to Penetrate the Notebook Computer Market.

      Our success depends upon our ability to sell our Crusoe microprocessors in volume to the small number of OEMs that manufacture notebook computers. Due to our software-based approach to microprocessor design, we have been required, and expect to continue to be required, to devote substantial resources to educate prospective customers in the notebook computer market about the benefits of our Crusoe products and to assist potential customers with their designs. In addition, since computer products generally are designed to incorporate a specific microprocessor, OEMs must design new products to utilize different microprocessors such as our Crusoe products. Given the complexity of these computer products and their many components, designing new products requires significant investments. For instance, OEMs may need to design new computer casings, basic input/output system software and motherboards. Our target customers

22


Table of Contents

may not choose our products for technical, performance, packaging, novelty, design cost or other reasons. If our Crusoe products fail to achieve widespread acceptance in the notebook computer market, we would likely never achieve revenue sufficient to sustain our business and the value of an investment in our common stock would likely decline significantly.
 
The Growth of Our Business Depends in Part upon the Development of Emerging Markets and Our Ability to Meet the Needs of These Markets.

      The growth of our business depends in part on acceptance and use of our products in new markets such as the high-density server market and new embedded processor applications. We depend on the ability of our target customers to develop new products and enhance existing products for these markets that incorporate our products and to introduce and promote their products successfully. These new markets often rely on newly developed technologies, which will require extensive development and marketing before widespread acceptance is achieved, so the new markets may grow slowly, if at all. If the new markets do not grow as we anticipate, our target customers do not incorporate our products into theirs, or our products are not widely accepted by end users, our growth would be impeded and we will not be able to factor the related revenues into our growth in the future. In addition, manufacturers within emerging markets may have widely varying requirements. To meet the requirements of different manufacturers and markets, we may be required to change our product design or features, sales methods or pricing policies. The costs of addressing these requirements could be substantial and could delay or prevent any improvement in our operating results.

 
The Cyclical Nature of the Semiconductor Industry Could Create Fluctuations in Our Operating Results.

      The semiconductor industry has historically been cyclical, and characterized by wide fluctuations in product supply and demand. From time to time, the industry has also experienced significant downturns, often in connection with, or in anticipation of, maturing product cycles and declines in general economic conditions. Industry downturns have been characterized by diminished product demand, production overcapacity and accelerated decline of average selling prices, and in some cases have lasted for more than a year. The industry experienced a downturn of this type in 1997 and 1998, and has been experiencing a downturn again since 2001. Our net product revenue has decreased in response to industry-wide fluctuations, and could decrease further. In addition, we may determine to lower our prices of our products to increase or maintain market share, which would likely decrease our operating results.

 
Our Operating Results Are Difficult to Predict and Fluctuate Significantly, and a Failure to Meet the Expectations of Securities Analysts or Investors Has Resulted in a Substantial Decline in Our Stock Price.

      Our operating results fluctuate significantly from quarter to quarter and we expect our results to fluctuate in the future. You should not rely on quarter-to-quarter comparisons of our results of operations as an indication of our future performance. Our stock price declined substantially since our stock began trading publicly in November of 2000. If our future operating results fail to meet or exceed the expectations of securities analysts or investors, our stock price would likely decline further in the future.

      Our results could fluctuate because of the amount of revenue we recognize or the amount of cash we spend in a particular period. For example, our results could fluctuate due to the following factors:

  •  the gain or loss of significant customers, or significant changes in their purchasing volume;
 
  •  the amount and timing of our operating expenses and capital expenditures;
 
  •  pricing concessions that we might grant on volume sales;
 
  •  the effectiveness of our product cost reduction efforts and those of our suppliers;
 
  •  changes in the average selling prices of our microprocessors or the products that incorporate them;
 
  •  charges to earnings for workforce reductions;

23


Table of Contents

  •  our ability to specify, develop, complete, introduce and market new products and technologies, and bring them to volume production in a timely manner; and
 
  •  changes in the mix of products that we sell.

      Our reliance on third parties for wafer fabrication, assembly, test and warehouse services also could contribute to fluctuations in our quarterly results, based upon factors such as the following:

  •  fluctuations in manufacturing yields;
 
  •  cancellations, changes or delays of deliveries to us by our manufacturer;
 
  •  the cost and availability of manufacturing, assembly and test capacity;
 
  •  delays in deliveries to customers of our products; and
 
  •  problems or delays resulting from shifting our products to smaller geometry process technologies or from designing our products to achieve higher levels of design integration.

      In addition, our results could fluctuate from quarter to quarter due to factors in our industry that are outside of our control, including the following factors:

  •  the timing, rescheduling or cancellation of customer orders;
 
  •  the varying length of our sales cycles;
 
  •  the availability and pricing of competing products and technologies, and the resulting effect on sales and pricing of our products;
 
  •  the availability and pricing of products that compete with products that incorporate our microprocessors;
 
  •  fluctuations in the cost and availability of complementary components that our customers require to build systems that incorporate our products;
 
  •  fluctuations in the cost and availability of raw materials, such as wafers, chip packages and chip capacitors;
 
  •  the rate of adoption and acceptance of new industry standards in our target markets;
 
  •  seasonality in some of our target markets;
 
  •  changes in demand by the end users of our customers’ products;
 
  •  variability of our customers’ product life cycles; and
 
  •  economic and market conditions in the semiconductor industry and in the industries served by our customers.

      A large portion of our expenses, including rent, salaries and capital leases, is fixed and difficult to reduce. Our expenses are based in part on expectations for our revenue. If our revenue does not meet our expectations, the adverse effect of the revenue shortfall upon our operating results may be acute in light of the fixed nature of our expenses. We make many shipments of our products at or near the end of the fiscal quarter, which makes it difficult to estimate or adjust our operating activities quickly in response to a shortfall in expected revenue.

 
Our Recent Reduction In Workforce May Adversely Affect the Morale and Performance of Our Personnel, Our Ability To Hire New Personnel and Our Operations.

      In July 2002, as part of our effort to reduce operating expenses, we announced a restructuring and related reduction in our workforce. Our restructuring plan included the termination of approximately 195 employees and contractors, which constituted approximately 40 percent of our workforce. As a result of the recent workforce reduction, we have incurred substantial costs related to severance and other employee-related costs.

24


Table of Contents

Our workforce reduction may also subject us to litigation risks and expenses. In addition, our restructuring plan may yield unanticipated consequences, such as attrition beyond our planned reduction in workforce. As a result of these reductions, our ability to respond to unexpected challenges may be impaired and we may be unable to take advantage of new opportunities. In addition, some of the employees who were terminated had specific and valuable knowledge or expertise, the loss of which may adversely affect our operations. Further, the reduction in force may reduce employee morale and may create concern among existing employees about job security, which may lead to increased attrition or turnover. As a result of these factors, our remaining personnel may decide to seek employment with more established companies, and we may have difficulty attracting new personnel that we might wish to hire in the future.
 
We Might Not Be Able to Execute on Our Business Plan if We Lose Key Management or Technical Personnel, on Whose Knowledge, Leadership and Technical Expertise We Rely, or if We Fail to Work Effectively With New Members of Our Management Team.

      Our success depends heavily upon the contributions of our key management and technical personnel, whose knowledge, leadership and technical expertise would be difficult to replace. Many of these individuals have been with us for several years and have developed specialized knowledge and skills relating to our technology and business. Others, including our president and chief executive officer, have joined us in senior management roles only recently. During 2002, we had significant changes in senior management. In April 2002, Matthew R. Perry joined us as chief executive officer and president, replacing Murray A. Goldman and R. Hugh Barnes, who served in positions of chief executive officer and president and chief operating officer, respectively, from October 2001 to April 2002. In June 2002 Svend-Olav Carlsen, our vice president of finance and corporate controller, began serving as acting chief financial officer. In August 2002, Ray Holzworth joined us as vice president of operations. In March 2003, Arthur L. Swift joined us as senior vice president of marketing. Our success will depend in part upon the ability of these new executives to work effectively together and with the rest of our employees to continue to develop our technology and manage the operation and growth of our business. All of our executive officers and key personnel are employees at will. We have no employment contracts and do not maintain key person insurance on any of our personnel. We might not be able to execute on our business plan if we were to lose the services of any of our key personnel. If any of these individuals were to leave Transmeta unexpectedly, we could face substantial difficulty in hiring qualified successors and could experience a loss in productivity while any such successor develops the necessary training and experience.

 
The Price of our Common Stock Has Been Volatile and is Subject to Wide Fluctuations.

      The market price of our common stock has been volatile and is likely to remain to be subject to wide fluctuations in the future. Many factors could cause the market price of our common stock to fluctuate, including:

  •  variations in our quarterly results;
 
  •  market conditions in our industry, the industries of our customers and the economy as a whole;
 
  •  announcements of technological innovations by us or by our competitors;
 
  •  introductions of new products or new pricing policies by us or by our competitors;
 
  •  acquisitions or strategic alliances by us or by our competitors;
 
  •  recruitment or departure of key personnel;
 
  •  the gain or loss of significant orders;
 
  •  the gain or loss of significant customers; and
 
  •  changes in the estimates of our operating performance or changes in recommendations by securities analysts.

25


Table of Contents

      In addition, the stock market generally and the market for semiconductor and other technology-related stocks in particular has experienced a decline during 2000, 2001 and through the third quarter of 2002, and could decline further, which could cause the market price of our common stock to fall for reasons not necessarily related to our business, results of operations or financial condition. The market price of our stock also might decline in reaction to events that affect other companies in our industry even if these events do not directly affect us. Accordingly, you may not be able to resell your shares of common stock at or above the price you paid. Securities class action litigation is often brought against a company following a period of volatility in the market price of its securities, and we are defending several purported securities class action lawsuits. Further, certain of our management and directors have also been sued in purported shareholder derivative actions. Although we believe that the lawsuits lack merit, an adverse determination could have a significant effect upon our business and materially affect the price of our stock. Moreover, regardless of the ultimate result, it is likely that the lawsuits will divert management’s attention and resources from other matters, which could also adversely affect our business and the price of our stock.

 
We Face Intense Competition in the Semiconductor Market; Our Competitors Are Much Larger Than We Are and Have Significantly Greater Resources; We May Not Be Able to Compete Effectively.

      The market for microprocessors is dominated by established firms and subject to rapid technological change. We face particularly strong competitive pressure in the United States and we believe that such pressure is increasing on a worldwide basis. Competition may cause price reductions, reduced gross margins and loss of market share, any one of which could significantly reduce our future revenue and increase our losses. For example, we may determine to lower the prices of our products in order to increase or maintain market share, which would likely increase our losses. Significant competitors include Intel, Advanced Micro Devices, VIA Technologies and licensees of technology from ARM Holdings and MIPS Technologies.

      Our current and potential competitors have longer operating histories, significantly greater financial, technical, product development and marketing resources, greater name recognition and significantly larger customer bases than we do. Our competitors may be able to develop products comparable or superior to those we offer, adapt more quickly than we do to new technologies, evolving industry trends and customer requirements, and devote greater resources to the development, promotion and sale of their products than we can. Many of our competitors also have well-established relationships with our existing and prospective customers and suppliers. As a result of these factors, many of our competitors, either alone or with other companies, have significant influence in our target markets that could outweigh any advantage that we may possess. For example, negotiating and maintaining favorable customer and strategic relationships are and will continue to be critical to our business. If our competitors use their influence to negotiate strategic relationships on more favorable terms than we are able to negotiate, or if they structure relationships that impair our ability to form strategic relationships, our competitive position and our business would be substantially damaged.

      Furthermore, our competitors may merge or form strategic relationships that might enable them to offer, or bring to market earlier, products that are superior to ours in terms of features, quality, pricing or other factors. We expect additional competition from other established and emerging companies and technologies. We may not be able to compete effectively against current and potential competitors, especially those with significantly greater resources and market leverage.

 
Our Products May Have Defects, Which Could Damage Our Reputation, Decrease Market Acceptance of Our Products, Cause Us to Lose Customers and Revenue, and Result in Liability to Us.

      Highly complex products such as our microprocessors may contain hardware or software defects or bugs for many reasons, including design issues or defective materials or manufacturing processes. Often, these defects and bugs are not detected until after the products have been shipped. If any of our products contain defects, or has reliability, quality or compatibility problems, our reputation might be damaged significantly and customers might be reluctant to buy our products, which could result in the loss of or failure to attract customers. In addition, these defects could interrupt or delay sales. We may have to invest significant capital and other resources to correct these problems. If any of these problems are not found until after we have commenced commercial production of a new product, we might incur substantial additional development

26


Table of Contents

costs. If we fail to provide solutions to the problems, such as software upgrades or patches, we could also incur product recall, repair or replacement costs. These problems might also result in claims against us by our customers or others. In addition, these problems might divert our technical and other resources from other development efforts. Moreover, we would likely lose, or experience a delay in, market acceptance of the affected product or products, and we could lose credibility with our current and prospective customers. This is particularly significant as we are a new entrant to a market dominated by large well-established companies.
 
We Derive a Substantial Portion of Our Revenue From a Small Number of Customers, and Our Revenue Would Decline Significantly if Any Major Customer Were to Cancel, Reduce or Delay a Purchase of Our Products.

      Sales to two customers in the aggregate accounted for 63% of net product revenue in 2002. These customers are located in Japan, which subjects us to economic cycles in that country. We expect that a small number of OEM customers and distributors will continue to account for a significant portion of our revenue. Our future success will depend upon the timing and size of future purchase orders, if any, from these customers and new customers and, in particular:

  •  the success of our customers in marketing products that incorporate our products;
 
  •  the product requirements of our customers; and
 
  •  the financial and operational success of our customers.

      We have entered into distributor agreements and rely in part on distributors and stocking representatives for sales of our products in large territories, including Japan, Taiwan, Hong Kong, Europe, China, Korea and North America. These agreements do not contain minimum purchase commitments. Additionally, we have entered into agreements with manufacturers’ representatives in North America and Europe. Any distributor, stocking representative or manufacturers’ representative that fails to emphasize sales of our products, chooses to emphasize alternative products or devices to promote products of our competitors might not sell a significant amount or any of our products. We expect that our sales to OEM customers will continue to be made on the basis of purchase orders rather than long-term commitments. In addition, customers can delay, modify or cancel orders without penalty. Many of our customers and potential customers are significantly larger than we are and have sufficient bargaining power to demand reduced prices and favorable nonstandard terms. The loss of any major customer, or the delay of significant orders from these customers, could reduce or delay our recognition of revenue.

 
Our Dependence on TSMC to Fabricate Wafers Limits Our Control Over the Production, Supply and Delivery of Our Products.

      The cost, quality and availability of third-party manufacturing operations are essential elements to the successful production of our products. We currently rely exclusively on TSMC to fabricate our wafers. We do not have a manufacturing agreement with TSMC that guarantees any particular production capacity or any particular price from TSMC. We place orders on a purchase order basis and TSMC may allocate capacity to other companies’ products while reducing deliveries to us on short notice. The absence of dedicated capacity means that, with little or no notice, TSMC could refuse to continue to fabricate all or some of the wafers that we require or change the terms under which it fabricates wafers. If TSMC were to stop manufacturing for us, we would likely be unable to replace the lost capacity in a timely manner. Transferring to another manufacturer would require a significant amount of time and money, and a smooth and timely transition would be unlikely. As a result, we could lose potential sales and fail to meet existing obligations to our customers. In addition, if TSMC were to change the terms under which it manufactures for us, our manufacturing costs could increase.

      Our reliance on third-party manufacturers exposes us to the following risks outside our control:

  •  unpredictability of manufacturing yields and production costs;
 
  •  interruptions in shipments;

27


Table of Contents

  •  potential lack of adequate capacity to fill all or part of the services we require;
 
  •  inability to control quality of finished products;
 
  •  inability to control product delivery schedules; and
 
  •  potential lack of access to key fabrication process technologies.

 
If We Fail to Forecast Demand for Our Products Accurately, We Could Lose Sales and Incur Inventory Losses.

      Because we only introduced our products in January 2000 and did not start volume shipments of commercial products until September 2000, we have little historical information about demand for our products. Many shipments of our products are made near the end of the fiscal quarter, which also makes it difficult to estimate demand for our products. The demand for our products depends upon many factors and is difficult to forecast. We expect that it will become more difficult to forecast demand as we introduce a larger number of products and as competition in the markets for our products intensifies. Significant unanticipated fluctuations in demand have caused, and in the future could cause, problems in our operations.

      The lead-time required to fabricate large volumes of wafers is often longer than the lead-time our customers provide to us for delivery of their product requirements. Therefore, we often must place our orders in advance of expected purchase orders from our customers. As a result, we have only a limited ability to react to fluctuations in demand for our products, which could cause us to have either too much or too little inventory of a particular product. If demand does not develop as we expect, we could have excess production. Excess production would result in excess inventories of finished products, which would use cash and could result in inventory write-downs and write-offs. We have limited capability to reduce ongoing production once wafer fabrication has commenced. For example, due to the sudden and significant decrease in actual and forecasted demand for our products during the second and third quarters of 2001, we recorded a net charge of $25.6 million to cost of revenue related to excess inventory and related purchase commitments. Further, as we introduce product enhancements and new products, and improve our manufacturing processes, demand for our existing products decreases. Conversely, if demand exceeds our expectations, TSMC, might not be able to fabricate wafers as quickly as we need them. Also, ASE, which provides our assembly and test services, might not be able to increase assembly functions in a timely manner. In that event, we would need to increase production and assembly rapidly at TSMC and ASE or find, qualify and begin production and assembly at additional manufacturers, which may not be possible within a time frame acceptable to our customers. The inability of TSMC and ASE to increase production rapidly enough could cause us to fail to meet customer demand. In addition, rapid increases in production levels to meet unanticipated demand could result in higher costs for manufacturing and other expenses. These higher costs could lower our gross margins.

 
We May Experience Manufacturing Difficulties That Could Increase the Cost and Reduce the Supply of Our Products.

      The fabrication of wafers for our microprocessors is a highly complex and precise process that requires production in a tightly controlled, clean room environment. Minute impurities, difficulties in the fabrication process, defects in the masks used to print circuits on a wafer or other factors can cause numerous die on each wafer to be nonfunctional. The proportion of functional die expressed as a percentage of total die on a wafer is referred to as product “yield.” Semiconductor companies frequently encounter difficulties in achieving expected product yields. During 2001, we experienced yield problems as we migrated our manufacturing processes to smaller geometries, which caused increases in our product costs, delays in product availability and diversion of engineering personnel. Even with functional die, normal variations in wafer fabrication can cause some die to run faster than others. Variations in speed yield could lead to excess inventory, a resulting unfavorable impact on gross margins and insufficient inventory of faster products, depending upon customer demand. Yield problems may not be identified and resolved until a product has been manufactured and can be analyzed and tested, if ever. As a result, yield problems are often difficult, time consuming and expensive to correct. Yield problems have in the past and could in the future hamper our ability to deliver our products to our customers in a timely manner.

28


Table of Contents

 
Our Dependence on ASE to Provide Assembly and Test Services Limits Our Control Over Production Costs and Product Supply.

      We rely on ASE for substantially all of our assembly and test services. As a result, we do not directly control our product delivery schedules. This lack of control could result in product shortages, which could increase our costs or delay delivery of our products. We do not have a contract with ASE for test and assembly services, and we typically procure these services from ASE on a per order basis. ASE could cease to perform all of the services that we require, or could change the terms upon which it performs services for us. Therefore, we may not be able to obtain assembly and testing services for our products on acceptable terms, or at all. If we are required to find and qualify alternative assembly or testing services, we could experience delays in product shipments, increased product costs or a decline in product quality.

 
Our California Facilities and the Facilities of Third Parties Upon Which We Rely to Provide Us Critical Services are Located in Regions that are Subject to Earthquakes and Other Natural Disasters.

      Our California facilities, including our principal executive offices, are located near major earthquake fault lines. If there is a major earthquake or any other natural disaster in a region where one of our facilities is located, our business could be materially and adversely affected. In addition, TSMC, upon which we currently rely to fabricate our wafers, and ASE, upon which we currently rely for substantially all of our assembly and test services, are located in Taiwan. Taiwan has experienced significant earthquakes and could be subject to additional earthquakes in the future. Any earthquake or other natural disaster in Taiwan could materially disrupt TSMC’s production capabilities and ASE’s assembly and test capabilities and could result in our experiencing a significant delay in delivery, or substantial shortage, of wafers and possibly in higher wafer prices.

 
If We Fail to Establish and Maintain Relationships With Key Participants in Our Target Markets, We May Have Difficulty Selling Our Products.

      In addition to our customers, we will need to establish and maintain relationships with companies that develop technologies that work in conjunction with our microprocessors. These technologies include operating systems, basic input/output systems, graphics chips, dynamic random access memory, or DRAM, and other hardware components and software that are used in computers. If we fail to establish and maintain these relationships, it would be more difficult for us to develop and market products with features that address emerging market trends.

 
If Our Products Are Not Compatible With the Other Components That Our Customers Design Into Their Systems, Sales of Our Products Could Be Delayed or Cancelled and a Substantial Portion of Our Products Could Be Returned.

      Our products are designed to function as components of a system. Our customers use our products in systems that have differing specifications and that require various other components, such as dynamic random access memory, or DRAM, and other semiconductor devices. If our customers’ systems are to function properly, all of the components must be compatible with each other. If our customers experience system-level incompatibilities between our products and the other components in their systems, we could be required to modify our products to overcome the incompatibilities or delay shipment of our products until the manufacturers of other components modify their products or until our customers select other components. These events would delay purchases of our products, cause orders for our products to be cancelled or result in product returns. System-level incompatibilities that are significant, or are perceived to be significant could also result in negative publicity and could significantly damage our business.

 
If Our Customers Are Not Able to Obtain the Other Components Necessary to Build Their Systems, Sales of Our Products Could Be Delayed or Cancelled.

      Suppliers of other components incorporated into our customers’ systems may experience shortages, which could reduce the demand for our products. For example, from time to time, the computer and semiconductor

29


Table of Contents

industries have experienced shortages of some materials and devices, such as memory components, displays, and storage devices. Our customers could defer or cancel purchases of our products if they are not able to obtain the other components necessary to build their systems.
 
There May Be Software Applications or Operating Systems That Are Not Compatible With Our Products, Which May Prevent Our Products from Achieving Market Acceptance and Prevent Us From Receiving Significant Revenue.

      Software applications, games or operating systems with machine-specific routines programmed into them can result in specific incompatibilities. If a particular software application, game or operating system is programmed in a manner that makes it unable to respond correctly to our microprocessor, it will appear to users of that software that our microprocessor is not compatible with PC software. We might encounter incompatibilities in the future. If any incompatibilities are significant or are perceived to be significant, our products might never achieve market acceptance and we might not receive significant revenue from product sales.

 
The Evolution of Our Business Could Place Significant Strain on Our Management Systems, Infrastructure and Other Resources, and Our Business May Not Succeed if We Fail to Manage Effectively.

      Our ability to implement our business plan in a rapidly evolving market requires effective planning and management process. Changes in our business plans could place significant strain on our management systems, infrastructure and other resources. In addition, we expect that we will continue to improve our financial and managerial controls and procedures. We will also need to expand, train and manage our workforce worldwide. Furthermore, we expect that we will be required to manage an increasing number of relationships with suppliers, manufacturers, customers and other third parties. If we fail to manage change effectively, our employee-related costs and employee turnover could increase and our business may not succeed.

 
Our Lengthy and Variable Sales Cycles Make It Difficult for Us to Predict When and if a Design Win Will Result in Volume Shipments.

      We depend upon other companies designing our microprocessors into their products, which we refer to as design wins. Many of our targeted customers consider the choice of a microprocessor to be a strategic decision. Thus our targeted customers may take a long time to evaluate our products, and many individuals may be involved in the evaluation process. We anticipate that the length of time between our initial contact with a customer and the time when we recognize revenue from that customer will vary. We expect our sales cycles to range from six to twelve months from the time we achieve a design win to the time the customer begins volume production of products that incorporate our microprocessors. We do not have historical experience selling our products that is sufficient for us to determine how our sales cycles will affect the timing of our revenue. Variations in the length of our sales cycles could cause our revenue to fluctuate widely from period to period. While potential customers are evaluating our products and before they place an order with us, we may incur sales and marketing expenses and expend significant management and engineering resources without any assurance of success. The value of any design win depends upon the commercial success of our customers’ products. If our customers cancel projects or change product plans, we could lose anticipated sales. We can offer no assurance that we will achieve further design wins or that the products for which we achieve design wins will ultimately be introduced or will, if introduced, be commercially successful.

 
If We Do Not Keep Pace With Technological Change, Our Products May Not Be Competitive and Our Revenue and Operating Results May Suffer.

      The semiconductor industry is characterized by rapid technological change, frequent new product introductions and enhancements, and ongoing customer demands for greater performance. In addition, the average selling price of any particular microprocessor product has historically decreased substantially over its life, and we expect that trend to continue. As a result, our products may not be competitive if we fail to

30


Table of Contents

introduce new products or product enhancements that meet evolving customer demands. It may be difficult or costly for us or we may not be able to enhance existing products to fully meet customer demands. For instance, in order to meet the demands of our customers for enhancement of our existing products, we may incur manufacturing or other costs that would harm our operating margins and financial condition. Further, we may not achieve further design wins with current customers unless we continue to meet their evolving needs by developing new products. The development of new products is complex, and we may not be able to complete development in a timely manner, or at all. To introduce and improve products on a timely basis, we must:

  •  accurately define and design new products to meet market needs;
 
  •  design features that continue to differentiate our products from those of our competitors;
 
  •  transition our products to new manufacturing process technologies;
 
  •  identify emerging technological trends in our target markets;
 
  •  anticipate changes in end-user preferences with respect to our customers’ products;
 
  •  bring products to market on a timely basis at competitive prices; and
 
  •  respond effectively to technological changes or product announcements by others.

      We believe that we will need to continue to enhance our products and develop new products to keep pace with competitive and technological developments and to achieve market acceptance for our products.

 
Our Products May Infringe the Intellectual Property Rights of Others, Which May Cause Us to Become Subject to Expensive Litigation, Cause Us to Incur Substantial Damages, Require Us to Pay Significant License Fees or Prevent Us From Selling Our Products.

      Our industry is characterized by the existence of a large number of patents and frequent claims and related litigation regarding patent and other intellectual property rights. We cannot be certain that our products do not and will not infringe issued patents, patents that may be issued in the future, or other intellectual property rights of others. In addition, leading companies in the semiconductor industry have extensive intellectual property portfolios with respect to semiconductor technology. From time to time, third parties, including these leading companies, may assert exclusive patent, copyright, trademark and other intellectual property rights to technologies and related methods that are important to us. We expect that we may become subject to infringement claims as the number of products and competitors in our target markets grows and the functionality of products overlaps. We have received, and may in the future receive, communications from third parties asserting patent or other intellectual property rights covering our products. Litigation may be necessary in the future to defend against claims of infringement or invalidity, to determine the validity and scope of the proprietary rights of others, to enforce our intellectual property rights, or to protect our trade secrets. We may also be subject to claims from customers for indemnification. Any resulting litigation, regardless of its resolution, could result in substantial costs and diversion of resources.

      If it were determined that our products infringe the intellectual property rights of others, we would need to obtain licenses from these parties or substantially reengineer our products in order to avoid infringement. We might not be able to obtain the necessary licenses on acceptable terms, or at all, or to reengineer our products successfully. Moreover, if we are sued for infringement and lose the suit, we could be required to pay substantial damages or be enjoined from licensing or using the infringing products or technology. Any of the foregoing could cause us to incur significant costs and prevent us from selling our products.

 
If We Are Unable to Protect Our Proprietary Rights Adequately, Our Competitors Might Gain Access to Our Technology and We Might Not Compete Successfully In Our Market.

      We believe that our success will depend in part upon our proprietary technology. We rely on a combination of patents, copyrights, trademarks, trade secret laws and contractual obligations with employees and third parties to protect our proprietary rights. These legal protections provide only limited protection and may be time consuming and expensive to obtain and enforce. If we fail to protect our proprietary rights

31


Table of Contents

adequately, our competitors might gain access to our technology. As a result, our competitors might offer similar products and we might not be able to compete successfully in our market. Moreover, despite our efforts to protect our proprietary rights, unauthorized parties may copy aspects of our products and obtain and use information that we regard as proprietary. Also, our competitors may independently develop similar, but not infringing, technology, duplicate our products, or design around our patents or our other intellectual property. In addition, other parties may breach confidentiality agreements or other protective contracts with us, and we may not be able to enforce our rights in the event of these breaches. Furthermore, we expect that we will increase our international operations in the future, and the laws of many foreign countries do not protect our intellectual property rights to the same extent as the laws of the United States. We may be required to spend significant resources to monitor and protect our intellectual property rights.

      Our pending patent and trademark applications may not be approved. Our patents, including any patents which may result from our patent applications may not provide us with any competitive advantage or may be challenged by third parties. If challenged, our patents might not be upheld or their claims could be narrowed. Any litigation surrounding our rights could force us to divert important financial and other resources from our business operations.

 
We Will Not Be Able to Grow Our Business if We Are Unable to Hire, Train and Retain Sales, Marketing, Operations, Engineering and Finance Personnel.

      To grow our business successfully and maintain a high level of quality, we will need to recruit, train, retain and motivate highly skilled sales, marketing, engineering and finance personnel. We will need to develop our sales and marketing organizations in order to increase market awareness of our products and to increase revenue. In addition, as a company focused on the development of complex products, we will need to hire skilled engineering staff of various experience levels in order to meet our product roadmap. We may not be able to hire on a timely basis a sufficient number of skilled employees, which could lead to delays in product deliveries or the development of new products. Competition for skilled employees, particularly in the San Francisco Bay Area, is intense. We may have difficulty recruiting potential employees and retaining our key personnel if prospective or current employees perceive the equity component of our compensation package to be less valuable than that of other employers.

 
If We Fail to Meet the Continued Listing Requirements of the Nasdaq Stock Market, Our Common Stock Could be Delisted, Which Would Likely Result in a Further Decrease in the Trading Price and Liquidity of Our Common Stock.

      Our common stock is listed on the Nasdaq National Market. The Nasdaq Stock Market’s Marketplace Rules impose requirements for companies listed on the Nasdaq National Market to maintain their listing status. One of these requirements is that we must maintain a minimum closing bid price of $1.00 per share for our common stock. If we fail to meet this requirement for 30 consecutive business days, we will receive a “deficiency notice” from Nasdaq. Upon receipt of this notice, we would then have 90 calendar days to comply, and during this period the minimum closing bid price per share must be above $1.00 per share for 10 consecutive business days during this period to comply. Following this period, we could appeal to Nasdaq for a hearing regarding the determination to delist our common stock from the Nasdaq National Market. On March 21, 2003, the closing bid price of our common stock was $1.24 per share. Delisting could reduce the ability of holders of our common stock to purchase or sell shares as quickly and as inexpensively as they have done historically. For instance, failure to obtain listing on another market or exchange may make it more difficult for traders to sell our securities. Broker-dealers may be less willing or able to sell or make a market in our common stock. Not maintaining a listing on a major stock market may result in a decrease in the trading price of our common stock due to a decrease in liquidity, reduced analyst coverage and less interest by institutions and individuals in investing in our common stock.

32


Table of Contents

 
We May Make Acquisitions, Which Could Put a Strain on Our Resources, Cause Dilution to Our Stockholders and Adversely Affect Our Financial Results.

      We may acquire companies and technology to expand our business and for other strategic reasons. Integrating newly acquired organizations and technologies into our company could put a strain on our resources and be expensive and time consuming. We may not be successful in integrating acquired businesses or technologies and may not achieve anticipated revenue and cost benefits. In addition, future acquisitions could result in potentially dilutive issuances of equity securities or the incurrence of debt, contingent liabilities or incurrence of charges related to goodwill and other intangible assets, any of which could adversely affect our balance sheet and operating results. Moreover, we may not be able to identify future suitable acquisition candidates or, if we are able to identify suitable candidates, we may not be able to make these acquisitions on commercially reasonable terms or at all.

 
We Plan to Expand Our International Operations, and the Success of Our International Expansion Is Subject to Significant Uncertainties.

      We believe that we must expand our international sales and distribution operations to be successful. We have sold, and in the future we expect to sell a significant portion of our products to customers in Asia. As part of our international expansion, we have personnel in Taiwan, Japan and Europe who provide sales and customer support. In addition, we have appointed distributors, stocking representatives and manufacturers’ representatives to sell products in Japan, Taiwan, Hong Kong, Europe, China, Korea and North America. In attempting to conduct and expand business internationally, we are exposed to various risks that could adversely affect our international operations and, consequently, our operating results, including:

  •  difficulties and costs of staffing and managing international operations;
 
  •  fluctuations in currency exchange rates;
 
  •  unexpected changes in regulatory requirements, including imposition of currency exchange controls;
 
  •  longer accounts receivable collection cycles;
 
  •  import or export licensing requirements;
 
  •  potentially adverse tax consequences;
 
  •  political and economic instability; and
 
  •  potentially reduced protection for intellectual property rights.

      In addition, because we have suppliers that are located outside of the United States, we are subject to risks generally associated with contracting with foreign suppliers and may experience problems in the timeliness and the adequacy or quality of product deliveries.

 
Our Certificate of Incorporation and Bylaws, Stockholder Rights Plan and Delaware Law Contain Provisions That Could Discourage or Prevent a Takeover, Even if an Acquisition Would Be Beneficial to Our Stockholders.

      Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would be beneficial to our stockholders. These provisions include:

  •  establishing a classified board of directors so that not all members of our board may be elected at one time;
 
  •  providing that directors may be removed only “for cause” and only with the vote of 66 2/3% of our outstanding shares;
 
  •  requiring super-majority voting to amend some provisions in our certificate of incorporation and bylaws;

33


Table of Contents

  •  authorizing the issuance of “blank check” preferred stock that our board could issue to increase the number of outstanding shares and to discourage a takeover attempt;
 
  •  limiting the ability of our stockholders to call special meetings of stockholders;
 
  •  prohibiting stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;
 
  •  eliminating cumulative voting in the election of directors; and
 
  •  establishing advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at stockholder meetings.

      In addition, the stockholder rights, which we implemented in 2002, and Section 203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control.

 
If We Need Additional Financing, We May Not Be Able to Raise Further Financing or It May Only Be Available on Terms Unfavorable to Us or Our Stockholders.

      We believe that our available cash resources are sufficient to meet our anticipated working capital and capital expenditure requirements for at least the next twelve months. We might need to raise additional funds, however, to respond to business contingencies, which could include the need to:

  •  fund expansion;
 
  •  fund marketing expenditures;
 
  •  develop new products or enhance existing products;
 
  •  enhance our operating infrastructure;
 
  •  fund working capital if our revenue does not increase, or declines;
 
  •  hire additional personnel;
 
  •  respond to competitive pressures; or
 
  •  acquire complementary businesses or technologies.

      If we were to raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our stockholders would be reduced, and these newly issued securities might have rights, preferences or privileges senior to those of our then-existing stockholders. Additional financing might not be available on terms favorable to us, or at all. If adequate funds were not available or were not available on acceptable terms, our ability to fund our operations, take advantage of unanticipated opportunities, develop or enhance our products or otherwise respond to competitive pressures would be significantly limited.

 
Recently Enacted and Proposed Changes in Securities Laws and Regulations are Likely to Increase Our Costs.

      The Sarbanes-Oxley Act of 2002 that became law in July 2002 requires changes in some of our corporate governance, public disclosure and compliance practices. The Act also requires the SEC to promulgate new rules on a variety of subjects. In addition to final rules and rule proposals already made by the SEC, the National Association of Securities Dealers has proposed revisions to its requirements for companies, such as us, that are Nasdaq-listed. We expect these developments to increase our legal and financial compliance costs, and to make some activities, such as SEC reporting requirements, more difficult. Additionally, we expect these developments to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These developments could make it more difficult for us to attract qualified executive officers and attract and retain qualified members of our board of directors, particularly to serve on our audit committee. We are presently evaluating and monitoring regulatory developments and cannot estimate the timing or magnitude of additional costs we may incur as a result.

34


Table of Contents

 
Item 7A.      Quantitative and Qualitative Disclosures About Market Risk

      Interest Rate Risk. Our cash equivalents and short-term investments are exposed to financial market risk due to fluctuations in interest rates, which may affect our interest income. As of December 31, 2002, our cash equivalents and short-term investments included money market funds and short and medium term corporate bonds and earned interest at an average rate of 2.2%. Due to the relative short-term nature of our investment portfolio, our interest income is extremely vulnerable to sudden changes in market interest rates. We do not use our investment portfolio for trading or other speculative purposes.

      The table below presents principle amounts and related weighted average interest rates by year of maturity for our investment portfolio as of December 31, 2002 (in thousands):

                                           
2002 2003 Thereafter Total Fair Value





Cash equivalents
  $ 16,613                 $ 16,613     $ 16,613  
 
Average rate
    1.8 %                 1.8 %        
Short term investments
  $ 79,703     $ 33,000           $ 112,703     $ 112,837  
 
Average rate
    2.1 %     2.7 %           2.3 %        

      Foreign Currency Exchange Risk. All of our sales and substantially all of our expenses are denominated in U.S. dollars. As a result, we have relatively little exposure to foreign currency exchange risk. We do not currently enter into forward exchange contracts to hedge exposures denominated in foreign currencies or any other derivative financial instruments for trading or speculative purposes. However, in the event our exposure to foreign currency risk increases, we may choose to hedge those exposures.

35


Table of Contents

 
Item 8.      Financial Statements and Supplementary Data

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

      The following financial statements are filed as part of this Report:

         
Page

Report of Ernst & Young LLP, Independent Auditors
    37  
Consolidated Balance Sheets
    38  
Consolidated Statements of Operations
    39  
Consolidated Statements of Stockholders’ Equity
    40  
Consolidated Statements of Cash Flows
    41  
Notes to Consolidated Financial Statements
    42  

36


Table of Contents

REPORT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

The Board of Directors and Stockholders

Transmeta Corporation

      We have audited the accompanying consolidated balance sheets of Transmeta Corporation as of December 31, 2002 and 2001, and the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2002. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

      We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

      In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Transmeta Corporation at December 31, 2002 and 2001, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2002, in conformity with accounting principles generally accepted in the United States.

  /s/ ERNST & YOUNG LLP

San Jose, California

January 13, 2003 except for
 Note 15, as to which the date
 is March 25, 2003

37


Table of Contents

TRANSMETA CORPORATION

 
CONSOLIDATED BALANCE SHEETS
                       
December 31,

2002 2001


(In thousands, except for
share and per share data)
ASSETS
Current assets:
               
 
Cash and cash equivalents
  $ 16,613     $ 57,747  
 
Short-term investments
    112,837       183,941  
 
Accounts receivable, net of allowances for doubtful accounts of $90 and $0, in 2002 and 2001, respectively
    4,060       1,749  
 
Inventories
    10,937       1,388  
 
Prepaid expenses and other current assets
    4,722       7,091  
     
     
 
     
Total current assets
    149,169       251,916  
Property and equipment, net
    9,574       11,622  
Patents and patent rights, net
    36,623       43,469  
Other assets
    2,189       2,017  
     
     
 
     
Total assets
  $ 197,555     $ 309,024  
     
     
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
Current liabilities:
               
 
Accounts payable
  $ 2,311     $ 5,421  
 
Accrued compensation and related compensation liabilities
    3,195       5,129  
 
Other accrued liabilities
    8,216       6,553  
 
Current portion of accrued restructuring costs
    2,549        
 
Current portion of long-term payables
    16,000       15,000  
 
Current portion of long-term debt and capital lease obligations
    865       2,661  
     
     
 
     
Total current liabilities
    33,136       34,764  
Long-term payables, net of current portion
    17,449       28,904  
Long-term accrued restructuring costs, net of current portion
    5,456        
Long-term debt and capital lease obligations, net of current portion
    667       391  
Commitments and contingencies
               
Stockholders’ equity:
               
 
Convertible preferred stock, $0.00001 par value, at amounts paid in; Authorized shares — 5,000,000. None issued in 2002 and 2001
           
 
Common stock, $0.00001 par value, at amounts paid in;
               
   
Authorized shares — 1,000,000,000.
               
   
Issued and outstanding shares — 136,086,142 in 2002 and 132,234,558 in 2001
    601,119       603,464  
Treasury stock — 796,875 shares in 2002 and 2001
    (2,439 )     (2,439 )
Deferred stock compensation
    (3,039 )     (11,818 )
Accumulated other comprehensive income
    134       720  
Accumulated deficit
    (454,928 )     (344,962 )
     
     
 
     
Total stockholders’ equity
    140,847       244,965  
     
     
 
     
Total liabilities and stockholders’ equity
  $ 197,555     $ 309,024  
     
     
 

(See accompanying notes)

38


Table of Contents

TRANSMETA CORPORATION

 
CONSOLIDATED STATEMENTS OF OPERATIONS
                             
Years Ended December 31,

2002 2001 2000



(In thousands, except for per share data)
Net product revenue
  $ 24,247     $ 35,590     $ 16,180  
Cost of revenue
    17,127       48,694       9,461  
     
     
     
 
Gross profit (loss)
    7,120       (13,104 )     6,719  
     
     
     
 
Operating expenses:
                       
 
Research and development(1)(2)
    63,603       67,639       61,415  
 
In-process research and development
          13,600        
 
Selling, general and administrative(3)(4)
    29,917       35,460       27,045  
 
Restructuring charges(5)
    14,726              
 
Amortization of deferred charges, patents and patent rights
    11,392       17,556       10,416  
 
Impairment write-off of deferred charges
          16,564        
 
Stock compensation
    1,809       20,954       13,056  
     
     
     
 
   
Total operating expenses
    121,447       171,773       111,932  
     
     
     
 
Operating loss
    (114,327 )     (184,877 )     (105,213 )
 
Interest and other income
    4,962       14,686       9,174  
 
Interest expense
    (601 )     (1,060 )     (1,666 )
     
     
     
 
Net loss
  $ (109,966 )   $ (171,251 )   $ (97,705 )
     
     
     
 
Net loss per share — basic and diluted
  $ (0.82 )   $ (1.33 )   $ (2.18 )
     
     
     
 
Weighted average shares outstanding — basic and diluted
    134,719       129,002       44,741  
     
     
     
 


(1)  Excludes $4,364, $8,292 and $5,557 in amortization of deferred stock compensation for the year ended December 31, 2002, 2001 and 2000, respectively.
 
(2)  Excludes $(408) and $2,006 in variable stock compensation for the year ended December 31, 2002 and 2001, respectively.
 
(3)  Excludes $950, $8,460 and $7,499 in amortization of deferred stock compensation for the year ended December 31, 2002, 2001 and 2000, respectively.
 
(4)  Excludes $(1,360) and $2,196 in variable stock compensation for the year ended December 31, 2002 and 2001, respectively.
 
(5)  Excludes $(1,737) in amortization of deferred stock compensation related to employee terminations for year ended December 31, 2002.

(See accompanying notes)

39


Table of Contents

TRANSMETA CORPORATION

 
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
                                                                 
Notes Accumulated
Convertible Receivable Deferred Other Total
Preferred Common Treasury from Stock Comprehensive Accumulated Stockholders’
Stock Stock Stock Stockholders Compensation Income/(Loss) Deficit Equity








(In thousands, except for share and per share data)
Balance at December 31, 1999
  $ 134,980     $ 7,183     $     $ (3,071 )   $     $ (3 )   $ (76,006 )   $ 63,083  
Issuance of 7,040,000 shares of Series G convertible preferred stock to investors for cash at $12.50 per share, net of issuance costs of $58,000
    87,942                                           87,942  
Issuance of 14,950,000 shares of common stock in initial public offering, net of issuance costs of $24.4 million
          289,638                                     289,638  
Conversion of preferred stock into 73,174,342 shares of common stock
    (222,922 )     222,922                                      
Issuance of 5,312,768 shares of common stock to employees under option exercises, net of repurchases
          15,225             (14,681 )                       544  
Issuance of 80,000 shares of common stock upon exercise of a warrant
          50                                     50  
Stock compensation in connection with severance arrangement
          945                                     945  
Issuance of warrants to purchase 8,000 shares of common stock in connection with consulting agreement
          30                                     30  
Issuance of 1,200,000 shares of common stock to a development partner
          6,750                                     6,750  
Issuance of 1,200,000 shares in connection with the conversion of a note
          433                                     433  
Stock compensation
          46,044                   (46,044 )                  
Amortization of deferred stock compensation
                            13,056                   13,056  
Other comprehensive income — unrealized gain on available-for-sale investments, net
                                  150             150  
Net loss
                                        (97,705 )     (97,705 )
     
     
     
     
     
     
     
     
 
Comprehensive income/(loss)
                                              (97,555 )
     
     
     
     
     
     
     
     
 
Balance at December 31, 2000
          589,220             (17,752 )     (32,988 )     147       (173,711 )     364,916  
Issuance costs related to issuance of shares of common stock in initial public offering
          (256 )                                   (256 )
Issuance of 1,995,457 shares of common stock to employees under option exercises and employee stock purchase plan, net of repurchases
          2,371                                     2,371  
Issuance of 798,649 shares of common stock in connection with the purchase of patents and patent rights
          13,813                                     13,813  
Issuance of 618,817 shares of common stock in connection with net warrant exercises
          170                                     170  
Stock compensation in connection with employee severance arrangement
          75                                     75  
Issuance of 1,000,000 shares in connection with the purchase of in- process research and development
          13,600                                     13,600  
Stock compensation
          (1,960 )           1,744       21,170                   20,954  
Purchase of 796,875 shares of treasury stock in exchange for cancellation of shareholder notes
                (2,439 )     2,439                          
Reduction of shareholder notes relating to termination of officers and application of non-recourse accounting to remaining notes
          (13,569 )           13,569                          
Other comprehensive income — unrealized gain on available-for-sale investments, net
                                  573             573  
Net loss
                                        (171,251 )     (171,251 )
     
     
     
     
     
     
     
     
 
Comprehensive income/(loss)
                                              (170,678 )
     
     
     
     
     
     
     
     
 
Balance at December 31, 2001
          603,464       (2,439 )           (11,818 )     720       (344,962 )     244,965  
Issuance of 3,511,101 shares of common stock to employees under option exercises and employee stock purchase plan, net of repurchases
          4,168                                     4,168  
Stock compensation
          (5,201 )                 8,779                   3,578  
Repayment of notes from stockholders
          456                                     456  
Variable stock compensation
          (1,768 )                                   (1,768 )
Other comprehensive income — unrealized gain/(loss) on available-for-sale investments, net
                                  (586 )           (586 )
Net loss
                                        (109,966 )     (109,966 )
     
     
     
     
     
     
     
     
 
Comprehensive income/(loss)
                                              (110,552 )
     
     
     
     
     
     
     
     
 
Balance at December 31, 2002
  $     $ 601,119     $ (2,439 )   $     $ (3,039 )   $ 134     $ (454,928 )   $ 140,847  
     
     
     
     
     
     
     
     
 

(See accompanying notes)

40


Table of Contents

TRANSMETA CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

                             
Years Ended December 31,

2002 2001 2000



(In thousands)
Cash flows from operating activities:
                       
 
Net loss
  $ (109,966 )   $ (171,251 )   $ (97,705 )
 
Adjustments to reconcile net loss to net cash used in operating activities:
                       
   
Stock compensation
    1,809       20,954       13,056  
   
Depreciation
    5,888       6,494       6,091  
   
Loss on disposal of fixed assets, net
    148              
   
Allowance for doubtful accounts
    90              
   
Amortization of other assets
    201       190        
   
Fair value of equity instruments issued for services
          170       30  
   
Stock compensation in connection with severance agreement
          75       945  
   
Amortization of deferred charges, patents and patent rights
    11,392       17,556       10,416  
   
Impairment write-off of deferred charges
          16,564        
   
Accretion of interest payable to a development partner
                45  
   
Write-off of purchased in-process research and development
          13,600        
   
Non cash restructuring charges
    1,629              
 
Changes in operating assets and liabilities:
                       
   
Accounts receivable
    (2,401 )     1,549       (3,298 )
   
Inventories
    (9,549 )     14,065       (15,453 )
   
Prepaid expenses and other current assets
    2,320       730       (6,209 )
   
Other non-current assets
    (103 )     (904 )      
   
Accounts payable and accrued liabilities
    (3,381 )     (275 )     13,532  
   
Accrued restructuring charges
    8,005              
   
Deposits received under subleasing agreements
          (138 )     (93 )
     
     
     
 
Net cash used in operating activities
    (93,918 )     (80,621 )     (78,643 )
     
     
     
 
Cash flows from investing activities:
                       
 
Purchase of available-for-sale investments
    (178,596 )     (255,610 )     (526,218 )
 
Proceeds from sale or maturity of available-for-sale investments
    249,114       155,600       462,811  
 
Purchase of property and equipment
    (5,581 )     (7,634 )     (8,036 )
 
Loans to founders
          5,446       (5,250 )
 
Payment to development partner
    (6,000 )     (3,500 )     (5,000 )
 
Purchase of patents and patent rights
    (9,000 )     (12,041 )      
 
Other assets
    (258 )     (466 )     (326 )
     
     
     
 
Net cash provided by/ (used in) investing activities
    49,679       (118,205 )     (82,019 )
     
     
     
 
Cash flows from financing activities:
                       
 
Net proceeds from issue of preferred stock
                87,942  
 
Net proceeds from initial public offering of common stock
          (256 )     289,638  
 
Common stock issued under stock option plans and employee stock purchase programs
    4,168       2,371       544  
 
Repayment of notes from stockholders
    456              
 
Issuance of common stock upon exercise of a warrant
                50  
 
Proceeds from debt and capital lease obligations
    1,140             1,248  
 
Repayment of debt and capital lease obligations
    (2,659 )     (5,286 )     (5,661 )
     
     
     
 
Net cash provided by/(used in) financing activities
    3,105       (3,171 )     373,761  
     
     
     
 
Change in cash and cash equivalents
    (41,134 )     (201,997 )     213,099  
Cash and cash equivalents at beginning of period
    57,747       259,744       46,645  
     
     
     
 
Cash and cash equivalents at end of period
  $ 16,613     $ 57,747     $ 259,744  
     
     
     
 
Supplemental disclosure of cash paid during the period:
                       
 
Cash paid for interest
  $ 639     $ 908     $ 1,534  
 
Cash paid for taxes
                1  
Supplemental disclosure of non-cash financing and investing activities:
                       
 
Issuance of warrants
                30  
 
Issuance of common stock in connection with net exercise of warrants
          170        
 
Issuance of common stock to employees for notes receivable
          40       14,817  
 
Issuance of common stock upon conversion of a note payable to development partner
                433  
 
Issuance of common stock in connection with purchase of patent and patent rights
          13,813        
 
Issuance of common stock in connection with purchased in-process research and development
          13,600        
 
Issuance of common stock in connection with license agreement
                6,750  
 
Purchase of treasury stock in exchange for cancellation of shareholder notes
          2,439        
 
Issuance of payable to development partner
                5,000  

(See accompanying notes)

41


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.     Overview

 
The Company

      Transmeta develops and sells software-based microprocessors and develops additional hardware, software, and system technologies that enable manufacturers to build highly efficient computing systems characterized by low power consumption, reduced heat dissipation and the high performance required to run standard x86 compatible programs. The Company originally developed its family of Crusoe microprocessors for lightweight notebook computers and other mobile computing devices, but has developed and is continuing to develop microprocessors suitable for a variety of existing and emerging end markets in which energy and thermal efficiency along with x86 software compatibility are desirable.

      Transmeta was incorporated in California as Transmeta Corporation on March 3, 1995, and was principally engaged in research and development, marketing, sales, raising capital, establishing sources of supplies, commencing production and building its management team through January 2000. Substantially all of Transmeta’s revenue was derived from technology license agreements with development partners prior to this period. In January 2000, the Company introduced its Crusoe family of microprocessors and subsequently began to recognize product revenue from sales of microprocessor products, prototypes and development systems. Effective October 26, 2000, Transmeta reincorporated as a Delaware corporation.

 
Fiscal Year

      Transmeta’s fiscal year ends on the last Friday in December. For ease of presentation, the accompanying financial statements have been shown as ending on December 31 and calendar quarter ends for all annual and quarterly financial statement captions. Fiscal years 2002, 2001 and 2000 consisted of 52 weeks each and ended on December 27, December 28 and December 29, respectively.

 
Stock Split

      On October 26, 2000, the Company effected a 2-for-1 stock split of its common stock. All share and per share amounts have been retroactively adjusted to reflect this split.

2.     Summary of Significant Accounting Policies

 
Principles of Consolidation

      The accompanying consolidated financial statements include the financial statements of Transmeta and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

 
Use of Estimates

      The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements. Actual results could differ from those estimates. Significant estimates made in preparing the financial statements include inventory valuations, long-lived and intangible asset valuations, restructuring charges and revenue reserves.

 
Concentrations of Credit Risk

      Financial instruments that potentially subject the Company to credit risk consist primarily of cash equivalents, short-term investments and accounts receivable. Substantially all of the Company’s cash equivalents are invested in highly liquid money market funds and commercial securities with high-quality financial institutions in the United States. Short-term investments consist of U.S. government and commercial

42


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

bonds and notes. The Company performs ongoing credit evaluations of its customers, maintains an allowance for potential credit losses and does not generally require collateral.

 
Supplier Concentrations

      The Company depends on a single or limited number of outside contractors to fabricate, assemble and test its semiconductor devices. While the Company seeks to maintain a sufficient level of supply and endeavors to maintain ongoing communications with suppliers to guard against interruptions or cessation of supply, business and results of operations could be adversely affected by a stoppage or delay of supply from these vendors.

 
Revenue Recognition

      The Company recognizes revenue from products sold when persuasive evidence of an arrangement exists, the price is fixed or determinable, shipment is made and collectibility is reasonably assured. The Company accrues for estimated sales returns, and other allowances at the time of shipment. Certain of the Company’s product sales are made to distributors under agreements allowing for price protection and/or right of return on unsold products. The Company defers recognition of revenue on these sales until the distributors sell the products. The Company may also sell certain products with “End of Life” status to its distributors under special arrangements without price protection or return privileges for which revenue is recognized upon transfer of title, typically shipment.

 
Shipping and Handling Costs

      Shipping and handling costs are expensed as incurred and included in cost of revenue in the Company’s results of operations.

 
Comprehensive Income/(Loss)

      Net comprehensive loss includes the Company’s net loss, as well as accumulated comprehensive income/(loss) on available-for-sale investments. Net comprehensive loss for the years ended December 31, 2002, 2001 and 2000, respectively, is as follows:

                         
Years Ended December 31,

2002 2001 2000



(In thousands)
Net loss
  $ (109,966 )   $ (171,251 )   $ (97,705 )
Net change in other comprehensive income/(loss) — unrealized gain/(loss) on investments
    (586 )     573       150  
     
     
     
 
Net comprehensive loss
  $ (110,552 )   $ (170,678 )   $ (97,555 )
     
     
     
 
 
Cash Equivalents and Short-term Investments

      Highly liquid debt securities with insignificant interest rate risk and original maturities of three months or less are classified as cash equivalents. Debt securities with maturities greater than three months and remaining maturities less than one year are available-for-sale and are classified as short-term investments. Securities with maturity dates greater than one year are also classified as short-term investments as they are considered to be available-for-sale securities.

      All of Transmeta’s short-term investments were classified as available-for-sale as of the balance sheet dates presented and, accordingly, are reported at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income/(loss) in stockholders’ equity. Fair values of cash

43


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

equivalents approximated original cost due to the short period of time to maturity. The cost of securities sold is based on the specific identification method. Realized gains or losses and declines in value, if any, judged to be other than temporary on available-for-sale securities are reported in interest income or expense.

 
Fair Values of Financial Instruments

      The fair values of Transmeta’s cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, and accounts payable and accrued liabilities approximate their carrying values due to the short-term nature of those instruments.

      The fair values of short-term and long-term capital lease obligations are estimated based on current interest rates available to Transmeta for debt instruments with similar terms, degrees of risk and remaining maturities. The carrying values of these obligations approximate their respective fair values.

 
Inventories

      Inventories are stated at the lower of cost (first-in, first-out) or market. Write-downs to reduce the carrying value of excess and obsolete, slow moving and non-usable inventory to net realizable value are charged to cost of revenue.

 
Property and Equipment

      Property and equipment are recorded at cost. Depreciation and amortization have been provided on the straight-line method over the related asset’s estimated useful life ranging from three to five years. Leasehold improvements and assets recorded under capital leases are amortized on a straight-line basis over the lesser of the related asset’s estimated useful life or the remaining lease term.

 
Valuation of Long-Lived and Intangible Assets

      Transmeta’s accounting policy related to the valuation and impairment of long-lived assets is in accordance with the Financial Accounting Standards Board’s (FASB) Statement of Financial Accounting Standards (SFAS) 144, “Accounting for the Impairment or Disposal of Long-Lived Assets”. In accordance with our policy, at the end of each accounting period we evaluate our long-lived and intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of long-lived assets may not be recoverable. Recoverability of assets to be held and used is determined by comparing the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds the future undiscounted cash flows the asset is considered to be impaired and the impairment charge recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset.

 
Research and Development

      Costs to develop Transmeta’s products are expensed as incurred in accordance with the FASB’s SFAS 2, “Accounting for Research and Development Costs,” which establishes accounting and reporting standards for research and development costs.

      Transmeta accounts for software development costs in accordance with the FASB’s SFAS 86, “Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed,” which requires capitalization of certain software development costs once technological feasibility for the software component is established and research and development activities for the hardware component are completed. Based on Transmeta’s development process, the time period between the establishment of technological feasibility and completion of the hardware component and the release of the product is short and capitalization of internal development costs has not been material to date.

44


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

 
Income Taxes

      Transmeta accounts for income taxes in accordance with the FASB’s SFAS 109, “Accounting for Income Taxes”, which requires the use of the liability method in accounting for income taxes. Under SFAS 109, deferred tax assets and liabilities are measured based on differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws that will be in effect when differences are expected to reverse.

 
Warranty

      Transmeta typically provides a warranty that includes factory repair services or replacement as needed for replacement parts on its products for a period of one year from shipment. Transmeta records a provision for estimated warranty costs upon shipment of its products. Warranty costs have been within management’s expectations to date and have not been material.

 
Advertising Expenses

      All advertising costs are expensed as incurred. To date, advertising costs have not been material.

 
Net Loss Per Share

      Basic and diluted net loss per share is presented in conformity with the FASB’s SFAS 128, “Earnings Per Share”, for all periods presented. Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during each period, less weighted-average shares subject to repurchase.

      The following table presents the computation of basic and diluted net loss per share:

                           
Years Ended December 31,

2002 2001 2000



(In thousands, except per share amounts)
Basic and diluted:
                       
 
Net loss
  $ (109,966 )   $ (171,251 )   $ (97,705 )
     
     
     
 
Basic and diluted:
                       
 
Weighted average shares outstanding
    134,902       132,779       51,016  
 
Less: Weighted average shares subject to repurchase
    (183 )     (3,777 )     (6,275 )
     
     
     
 
 
Weighted average shares used in computing basic and diluted net loss per share
    134,719       129,002       44,741  
     
     
     
 
Net loss per share — basic and diluted
  $ (0.82 )   $ (1.33 )   $ (2.18 )
     
     
     
 

      The Company has excluded all outstanding stock options and shares subject to repurchase from the calculation of basic and diluted net loss per share because these securities are antidilutive for all periods presented. Options and warrants to purchase 32,917,730, 22,885,437 and 18,274,614 shares of common stock in 2002, 2001 and 2000, respectively, determined using the treasury stock method, were not included in the computation of diluted net loss per share because the effect would be antidilutive. These securities, had they been dilutive, would have been included in the computation of diluted net loss per share using the treasury stock method.

45


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

 
Stock-Based Compensation

      Transmeta has employee stock plans that are described more fully in Note 11. The Company accounts for its stock options and equity awards in accordance with the provisions of Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees,” (APB 25) and related interpretations and has elected to follow the “disclosure only” alternative prescribed by the FASB’s SFAS 123, “Accounting for Stock-Based Compensation”. Expense associated with stock-based compensation is amortized on an accelerated basis over the vesting period of the individual award consistent with the method described in FASB Interpretation 28. Accordingly, approximately 59% of the unearned deferred compensation is amortized in the first year, 25% in the second year, 12% in the third year, and 4% in the fourth year following the date of grant. Pursuant to SFAS 123, Transmeta discloses the pro forma effect of using the fair value method of accounting for its stock-based compensation arrangements.

      For purposes of pro forma disclosures, the estimated fair value of options is amortized to pro forma expense over the option’s vesting period using an accelerated graded method. Pro forma information follows:

                         
Years Ended December 31,

2002 2001 2000



(In thousands, except per share data)
Net loss, as reported
  $ (109,966 )   $ (171,251 )   $ (97,705 )
Add: Stock-based employee compensation expense included in reported net loss, net of related tax effects
  $ 1,809     $ 20,954     $ 13,056  
Less: Total stock-based employee compensation expense under fair value based method for all awards, net of related tax effects
  $ (41,377 )   $ (39,648 )   $ (27,757 )
Pro forma net loss
  $ (149,534 )   $ (189,945 )   $ (112,406 )
Basic and diluted net loss per share — as reported
  $ (0.82 )   $ (1.33 )   $ (2.18 )
Basic and diluted net loss per share — pro forma
  $ (1.11 )   $ (1.47 )   $ (2.51 )

      See Note 11 for a discussion of the assumptions used in the option pricing model and estimated fair value of employee stock options.

      Options and warrants granted to consultants and vendors are accounted for at fair value determined by using the Black-Scholes method in accordance with Emerging Issues Task Force (EITF) Issue No. 96-18. The assumptions used to value stock-based awards to consultants and vendors are similar to those used for employees except that the respective contractual life of the warrant or option was used instead of the estimated life.(see Note 11).

      Due to the resignation in fiscal 2001 of certain officers and the treatment of the notes they issued to the Company in order to early exercise their options, the Company is accounting for all remaining stockholder notes that were issued to purchase shares of the Company’s common stock as if such notes had terms equivalent to non-recourse notes. As a result, in fiscal 2001 the Company recorded additional stock compensation expense to write-off all accrued interest related to its remaining stockholder notes and recorded an adjustment to its balance sheet to reduce common stock and reduce notes receivable from stockholders by the remaining amounts owed under the stockholder notes. This entry did not have a material impact on stockholders’ equity.

      In addition, under the terms of the outstanding stockholder notes, interest continues to accrue until the notes are paid. In assessing these notes as non-recourse, the underlying purchase price for the shares is not deemed to be fixed until the notes have been paid or otherwise settled. Accordingly, the Company determined that variable accounting is to be applied to these note arrangements as long as the notes remain outstanding. Under variable accounting, the Company records compensation expense for the vested shares for the excess, if

46


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

any, of the current market value of the shares over the then current principle amount of the notes and accrued interest, determined separately for each outstanding stockholder note. This variable accounting resulted in the Company recording a credit to stock compensation expense of $1.8 million in fiscal 2002 resulting from a lower share price of the Company’s common stock at the end of fiscal 2002 compared to the end of fiscal 2001. Stock compensation expense related to variable accounting was $2.5 million in fiscal 2001 and $0 in fiscal 2000. The market value of the Company’s common stock was $1.21 and $2.22 per share at the end of fiscal 2002 and 2001, respectively. During the remaining life of these outstanding stockholder notes, the Company’s reported stock compensation will be adjusted upward (expense) or downward (benefit) at each period end, based on the above stated formula.

 
Recent Accounting Pronouncements

      In July 2002, the FASB issued SFAS 146 “Accounting for Costs Associated with Exit or Disposal Activities”, which addresses financial accounting and reporting for costs associated with exit or disposal activities and nullifies EITF Issue No. 94-3, “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)”. The principal difference between SFAS 146 and EITF 94-3 relates to the timing of the recognition of a liability for a cost associated with an exit or disposal activity. SFAS 146 requires that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred. A liability for an exit cost as generally defined in EITF 94-3 is to be recognized at the date of an entity’s commitment to an exit plan. SFAS 146 is effective for exit or disposal activities that are initiated after December 31, 2002. The Company accounted for its restructuring activity during fiscal 2002 under EITF 94-3. The Company does not expect the adoption of SFAS 146 to have a material impact on its financial position or results of operations.

      In November 2002, the FASB issued FASB Interpretation No. 45 (FIN 45), “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantee’s of Indebtedness of Others.” FIN 45 requires that upon issuance of a guarantee, a guarantor must recognize a liability for the fair value of an obligation assumed under a guarantee. FIN 45 also requires additional disclosures by a guarantor in its interim and annual financial statements about the obligations associated with guarantees issued. The recognition provisions of FIN 45 are effective for any guarantees issued or modified after December 31, 2002. The disclosure requirements are effective for financial statements of interim or annual periods ending after December 15, 2002. The Company’s adoption of FIN 45 did not have a material impact on its financial position or results of operations.

      In December 2002, the FASB issued SFAS 148 “Accounting for Stock-Based Compensation — Transition and Disclosure”, which amends SFAS 123 “Accounting for Stock-Based Compensation” and provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, SFAS 148 amends the disclosure requirements of SFAS 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reporting results. The transition guidance and annual disclosures provisions of SFAS 148 are effective for fiscal years ending after December 15, 2002. The interim disclosure provisions are effective for financial reports containing financial statements for interim periods beginning after December 15, 2002. The Company adopted the disclosure provisions of SFAS 148 for this Form 10-K. The Company will continue to account for stock-based compensation under the provisions of APB 25 “Accounting for Stock Issued to Employees” using the “intrinsic value” method. Accordingly, the adoption of SFAS 148 is not anticipated to have a material effect on the Company’s financial position, results of operations, or cash flows.

      In January 2003, the FASB issued FIN No. 46 “Consolidation of Variable Interest Entities.” FIN 46 requires a variable interest to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity’s activities or entitled to a receive a majority of the entity’s residual

47


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

returns or both. A variable interest entity is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A variable interest entity often holds financial assets, including loans or receivables, real estate or other property. A variable interest entity may be essentially passive or it may engage in research and development or other activities on behalf of another company. The consolidation requirements of FIN 46 apply immediately to variable interest entities created after January 31, 2003. The consolidation requirements apply to older entities in the first fiscal year or interim period beginning after June 15, 2003. Certain of the disclosure requirements apply to all financial statements issued after January 31, 2003, regardless of when the variable interest entity was established. The Company does not expect that the adoption of this standard will have a material impact on its financial position or results of operations.

3.     Financial Statement Components

 
Cash Equivalents and Short-Term Investments

      All cash equivalents and short-term investments as of December 31, 2002 and 2001 were classified as available-for-sale securities and consisted of the following:

                                   
Gross Gross
Amortized Unrealized Unrealized
Cost Gains Losses Fair Value




(In thousands)
As of December 31, 2002:
                               
 
Money market funds
  $ 16,613     $     $     $ 16,613  
 
Municipal obligations
    10,000                   10,000  
 
Federal agency discount notes
    33,000       82             33,082  
 
Commercial paper
    69,703       52             69,755  
     
     
     
     
 
 
Total available-for-sale securities
  $ 129,316     $ 134     $     $ 129,450  
     
     
     
     
 
 
Less amounts classified as cash equivalents
                            (16,613 )
                             
 
 
Total short-term investments
                          $ 112,837  
                             
 
As of December 31, 2001:
                               
 
Money market funds
  $ 52,015     $     $     $ 52,015  
 
Federal agency discount notes
    30,000       16             30,016  
 
Commercial paper
    157,014       704             157,718  
     
     
     
     
 
 
Total available-for-sale securities
  $ 239,029     $ 720     $     $ 239,749  
     
     
     
     
 
 
Less amounts classified as cash equivalents
                            (55,808 )
                             
 
 
Total short-term investments
                          $ 183,941  
                             
 

      The following is a summary of amortized costs and estimated fair values of debt securities by contractual maturity.

                   
Amortized Fair
Cost Value


(In thousands)
As of December 31, 2002:
               
 
Amounts maturing within one year
  $ 79,703     $ 79,755  
 
Amounts maturing after one year, within five years
  $ 33,000     $ 33,082  

48


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

 
Accounts Receivable

      Customers who accounted for more than 10% of Transmeta’s accounts receivable balance at December 31, 2002 and 2001 are as follows:

                   
December 31,

2002 2001


Customer:
               
 
Uniquest
    52 %     * %
 
Sharp
    15 %     * %
 
Mitac
    11 %     * %
 
Sonic Blue
    * %     44 %
 
Fujitsu
    * %     20 %
 
Sony Electronics
    * %     16 %
 
Toshiba
    * %     12 %


represents less than 10% of accounts receivable balance

      The Company maintains an allowance for doubtful accounts receivable based upon the expected collectibility of accounts receivable. During fiscal 2002 we increased our allowance for doubtful accounts from $0 at December 31, 2001 to $90,000 at December 31, 2002, which resulted in a charge to bad debt expense of $90,000. There were no other adjustments to the allowance for bad doubtful accounts during fiscal 2002. Additionally, net accounts receivable at December 31, 2002 and 2001 included a revenue reserve of $65,000 and $34,000, respectively.

 
Inventories

      The components of inventories as of December 31, 2002 and 2001 are as follows:

                 
December 31,

2002 2001


(In thousands)
Work in progress
  $ 8,545     $ 838  
Finished goods
    2,392       550  
     
     
 
    $ 10,937     $ 1,388  
     
     
 

      During the second quarter of fiscal 2001, Transmeta recorded a charge to cost of revenue totaling $28.1 million primarily related to the write-off of excess inventory and related non-cancelable purchase commitments. Inventory purchases and commitments are based upon product demand forecasts. The Company built inventory levels for certain components with long lead times and entered into commitments for certain components. Due to a sudden and significant decrease in demand for our products in fiscal 2001, inventory levels and purchase commitments exceeded the Company’s estimated requirements based on demand forecasts. The inventory charge was calculated based on inventory levels in excess of forecasted demand for each specific product. Subsequently, the Company recognized 100% gross margin of $0.7 million and $1.7 million in fiscal 2002 and 2001, respectively, related to the sale of previously written-off inventory. Additionally, the Company recognized 100% gross profit of $1.2 million and $0.8 million in fiscal 2002 and 2001, respectively, related to the reversal of previously accrued inventory related purchase commitments due to favorable settlements of such purchase commitments.

49


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

 
Property and Equipment

      Property and equipment consisted of the following:

                   
December 31,

2002 2001


(In thousands)
Furniture and fixtures
  $ 2,018     $ 2,466  
Computer equipment
    22,417       18,683  
Computer software
    9,246       9,746  
Leasehold improvements
    2,657       2,857  
     
     
 
      36,338       33,752  
Less accumulated depreciation and amortization
    (26,764 )     (22,130 )
     
     
 
 
Property and equipment, net
  $ 9,574     $ 11,622  
     
     
 

      The original cost of equipment recorded under capital lease arrangements included in property and equipment aggregated $1.0 million at 2002 and $4.4 million at 2001. Related accumulated depreciation was $1.0 million and $3.7 million in 2002 and 2001, respectively. Amortization expense related to assets under capital leases is included with depreciation expense.

 
Patents and Patent Rights

      Patents and patent rights, net consisted of the following:

                   
December 31,

2002 2001


(In thousands)
Patents and patent rights
  $ 47,920     $ 47,920  
Less accumulated amortization
    (11,297 )     (4,451 )
     
     
 
 
Patents and patent rights, net
  $ 36,623     $ 43,469  
     
     
 

      Amortization expense of $6.8 million and $4.5 million was recorded in fiscal 2002 and 2001, respectively, related to patents and patent rights. Future amortization expense related to patents and patent rights is as follows:

           
(In thousands)
2003
  $ 6,846  
2004
    6,846  
2005
    6,846  
2006
    6,846  
2007
    6,846  
2008
    2,393  
     
 
 
Total future amortization
  $ 36,623  
     
 

4.     Technology License Agreements

      In December 1997, Transmeta entered into a technology license agreement with IBM Corporation (IBM), which was amended in 1999 and again in 2000. The term of the original agreement was five years. In the first amendment, in November 1999, IBM relinquished certain of the worldwide license rights previously

50


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

obtained in exchange for commitments by Transmeta. These commitments included a payment of $33.0 million to IBM in various installments beginning in fiscal 2001 through fiscal 2004.

      The then net present value of the $33.0 million commitment (approximately $18.9 million) was recorded on the balance sheet as an element of deferred charges under license agreements with a corresponding liability. The liability is being accreted to its future value using the effective interest method at a rate of approximately 15% per annum and is being recorded as part of amortization of deferred charges, patents and patent rights. During 2001, Transmeta fulfilled its obligation to pay IBM the $4.0 million payment due on or before December 15, 2001 by negotiating a $3.5 million payment in June 2001. A scheduled payment of $6.0 million was made to IBM in December 2002 in accordance with the terms of the agreement. The future cash commitment to IBM at December 31, 2002 was as follows:

           
(In thousands)
2003
  $ 7,000  
2004
    16,000  
     
 
 
Total payments
    23,000  
Less unamortized discounts
    (4,815 )
     
 
Present value as recorded on the balance sheet
  $ 18,185  
     
 

      The convertibility of IBM’s convertible promissory note, issued with the original agreement entered into in December 1997, was fixed at 1,200,000 shares of Transmeta’s common stock as part of the amended agreement. The fair value of the embedded beneficial conversion feature of the amended convertible promissory note was estimated to be $3.2 million based on the Black-Scholes method using a dividend yield of 0%, a risk-free interest rate of 6.35%, an expected life of four years and a volatility factor of 0.8. The fair value was recorded as a deferred charge under license agreements and was credited to common stock.

      On September 28, 2000, Transmeta and IBM agreed to a further amendment to the technology license agreement. IBM relinquished the right to receive certain contingent payments in exchange for a fixed commitment to pay $5.0 million, which was paid in two installments during the fourth quarter of 2000. This charge was recorded as a deferred charge under license agreements.

      In February 1998, Transmeta also entered into a similar technology license agreement with Toshiba Corporation (Toshiba). In February 2000, Transmeta and Toshiba amended their technology license agreement and Toshiba relinquished certain of their worldwide license rights previously obtained from Transmeta in exchange for 1,200,000 shares of Transmeta common stock. The then current value of the common stock, $6.8 million, was recorded on the balance sheet as a deferred charge under license agreements.

      Through the fourth quarter of 2001, the deferred charges under license agreements have been amortized on a straight-line basis over the remaining period of the original license agreements. During the fourth quarter of 2001, as part of the Company’s routine procedures and due to the emergence of indicators of impairment, Transmeta performed an assessment of the carrying value its long-lived assets to be held and used. The assessment was performed in connection with the Company’s internal policies and pursuant to SFAS 121 because of the significant negative industry and economic trends and particularly because of the Company’s delayed shipments due to difficulties in bringing our new products into high volume distribution, which significantly affected the Company’s operations and expected future operating cash flows. The conclusion of that assessment was that future cash flows did not exceed the carrying value of all long-lived assets. As a result, during the fourth quarter of 2001, the Company recorded a charge of $16.6 million to write-off such deferred charges under license agreements based on the amount by which the carrying amount of these assets exceeded their fair value. Fair value was determined to be zero, and was based on future cash flows for the company as a whole. The assumptions supporting the estimated future cash flows reflect management’s best

51


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

estimates. Although the asset was impaired, the associated liability is in effect and will continue to accrete interest until the final payment is made, which is due in 2004.

5.     Patents and Patent Rights

      Patents and patent rights for microprocessor technology were acquired from Seiko Epson (Epson) in May 2001. Under the patent and patent rights agreement with Epson, Transmeta agreed to pay Epson a combination of $30 million cash and shares of the Company’s common stock valued at $10 million based upon the average of the closing stock price over a defined period. The Company recorded total consideration of $38.1 million consisting of $10.8 million of Transmeta common stock, $26.8 million as the net present value of cash payments and $0.5 million of acquisition costs on the balance sheet as an element of patents and patent rights. The Company paid Epson $7.5 million in cash and 766,930 shares of the Company’s unregistered common stock in May 2001. The Company paid Epson $7.5 million in cash in May 2002 in accordance with the terms of the agreement. The number of shares issued to Epson was calculated in accordance with the agreement; however for accounting purposes the value of the shares was determined using the closing price on the issuance date, or $14.10, resulting in a recorded value of $10.8 million. In 2003, the Company will issue additional shares of unregistered common stock with a market value of $1.0 million calculated in accordance with the terms of the agreement.

      Additional patent and patents rights for microprocessor technology were acquired from another third party in February 2001. In exchange for the acquired patent and patent rights, Transmeta agreed to pay a combination of $7.0 million cash and shares of the Company’s common stock valued at $3.0 million over a three year period. The Company recorded total consideration of $9.7 million consisting of the net present value of cash payments of $6.7 million and $3.0 million of Transmeta common stock. The Company paid $1.5 million and $4.0 million in cash in February 2002 and 2001, respectively. The Company issued 340,483 shares of the Company’s unregistered common stock in February 2002 with a market value of $1.0 million calculated in accordance with the terms of the agreement. The Company issued 31,719 shares of the Company’s unregistered common stock in February 2001 with a market value of $1.0 million calculated in accordance with the terms of the agreement.

      Patent and patent rights are amortized on a straight-line basis over their expected life of seven years. The present value of future cash payments due Epson and others in 2004 accrete interest using an effective interest methodology at 10% per annum. Total amortization for patents and patent rights during fiscal 2002 and 2001 was approximately $11.4 million and $4.5 million, respectively. Total commitments for patents and patent rights to Epson and others are as follows:

           
(In thousands)
2003
  $ 9,000  
2004
    7,500  
     
 
 
Total payments
    16,500  
Less unamortized discounts
    (1,236 )
     
 
Present value as recorded on the balance sheet
  $ 15,264  
     
 

6.     Purchased In-process Research and Development

      In April 2001, Transmeta licensed certain computing technologies and intellectual property from Advanced Micro Devices, Inc. (AMD), including AMD’s HyperTransport interconnect technology for its future products and technology initiatives. As consideration for the technology rights licensed under the agreement, the Company issued 1,000,000 unregistered shares of its common stock valued at $15.0 million based upon the average closing price of the Company’s stock prior to issuance; however, for accounting

52


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

purposes the value of the shares was determined using the closing price of the stock at the date of issuance, or $13.60, resulting in a recorded value of $13.6 million. The entire $13.6 million was expensed as purchased in-process research and development during the second quarter of 2001 because the HyperTransport technology is designed for use in products that were under development at the time of acquisition.

7.     Restructuring Charges

      In the second quarter of fiscal 2002, Transmeta recorded a $10.6 million restructuring charge as a result of the Company’s decision to cease development and productization of the TM6000 microprocessor. The restructuring charge consisted primarily of lease costs, equipment write-offs and other costs as the Company identified a number of leased facilities as well as leased and owned equipment that were no longer required.

      On July 18, 2002 and in connection with Transmeta’s decision to cease the development and productization of the TM6000 microprocessor, the Company terminated approximately 195 employees and contractors. As a result, the Company recorded severance and termination charges of $4.1 million in the third quarter of fiscal 2002, which excludes a credit of $1.7 million to deferred compensation expense related to stock option cancellations for terminated employees. Additionally, the Company paid approximately $531,000 for previously accrued compensation in the third quarter of fiscal 2002 in connection with the employee terminations. Of the approximately 195 employees and contractors that were terminated on July 18, 2002, approximately 44 were sales, marketing, and administrative employees and approximately 151 were research and development personnel. The Company’s workforce reduction was completed in the third quarter of fiscal 2002. Additionally, the Company vacated all excess facilities as of September 30, 2002.

      Accrued restructuring charges consist of the following at December 31, 2002 (in thousands):

                                 
Provision
Cumulative Drawdowns Balance at
Restructuring
December 31,
Charges Cash Non-Cash 2002




Charges recorded in the quarter ended June 30, 2002:
                               
Building leasehold costs
  $ 8,854     $ 667     $ 284     $ 7,903  
Property and equipment and software costs
    1,629       187       1,442        
Other
    141       141              
     
     
     
     
 
      10,624       995       1,726       7,903  
     
     
     
     
 
Charges recorded in the quarter ended September 30, 2002:
                               
Workforce reduction
    4,102       4,000             102  
     
     
     
     
 
    $ 14,726     $ 4,995     $ 1,726     $ 8,005  
     
     
     
     
 

8.     Commitments and Contingencies

      Transmeta leases its facilities and certain equipment under noncancelable operating leases expiring through 2008. Gross operating lease and rental expenses were $3.9 million in 2002, $4.9 million in 2001 and $5.6 million in 2000. The facility leases provide for a 4% annual base rent increase. During fiscal 2002, 2001 and 2000, Transmeta subleased a portion of its facilities. Sublease income was $122,000 in 2002, $547,000 in 2001 and $1.2 million in 2000. All sublease agreements expired during 2002.

      Additionally, Transmeta finances certain equipment and software under noncancelable lease agreements that are accounted for as capital leases. Under the terms of our current capital lease agreements, at the end of

53


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

the lease term, the Company has the option to purchase the leased equipment at a purchase price of approximately 10% of the original equipment value.

      At December 31, 2002, future minimum payments for capital and operating lease obligations are as follows:

                     
Capital Operating
Leases Leases


(In thousands)
Years ending December 31,
               
 
2003
  $ 888     $ 4,216  
 
2004
    371       4,241  
 
2005
    371       4,393  
 
2006
          4,544  
 
2007
          4,696  
 
Thereafter
          2,385  
     
     
 
   
Total minimum lease payments
    1,630     $ 24,475  
             
 
Less amount representing interest
    (129 )        
     
         
Present value of capital lease obligations
    1,501          
Less current portion
    834          
     
         
Non-current portion
  $ 667          
     
         

      Transmeta’s foundry relationship with TSMC allows the Company to cancel all outstanding purchase orders, but requires Transmeta to pay the foundry for expenses it has incurred in connection with the purchase orders through the date of cancellation. As of December 31, 2002, TSMC had incurred approximately $2.0 million of manufacturing expenses on the Company’s outstanding purchase orders.

9.     Debt

      Transmeta issued promissory notes to financing companies in the principal amounts of $1.4 million in 1999, which mature through January 2003. These notes bear interest at 10.5% and are secured by certain tangible assets with an aggregate net book value of approximately $78,000 as of December 31, 2002. No notes were issued during 2002, 2001 or 2000. In connection with the notes, Transmeta issued to the note holders warrants to purchase 735,032 shares of common stock. Warrants to purchase 685,032 shares of common stock were issued with an exercise price of $1.25 and expire between March 2004 and April 2008. Warrants to purchase 50,000 shares of common stock were issued with an exercise price of $3.00 and expire in May 2005. These warrants were assigned an aggregate value of $78,000 on the basis of Black-Scholes valuation models using the contractual lives ranging from six to ten years and a volatility of 0.80. The value of the warrants was recorded as a discount against the respective borrowings and is being amortized over the respective terms of the notes. The amount of discount accreted and recorded as interest expense for the years ended December 31, 2002, 2001 and 2000 was $0, $7,000 and $26,000, respectively.

      At December 31, 2002, aggregate future minimum principal payments on the obligations described above were $31,000 and are due in fiscal 2003.

10.     Stockholders’ Equity

      In November 2000, the Company completed its initial public offering (“the offering”) of 14,950,000 shares (including 1,950,000 shares in connection with the exercise of the underwriters’ over-allotment option) at a price to the public of $21.00 per share. Upon consummation of the offering, all

54


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

outstanding shares of the Company’s non-cumulative convertible preferred stock were automatically converted into an aggregate of 73,174,342 shares of common stock. As of December 31, 2002 and 2001 there were no preferred shares outstanding.

 
Common Stock Reserved for Issuance

      Shares reserved for future issuance are as follows:

                 
December 31,

2002 2001


Warrants outstanding
    1,046,228       1,046,228  
Options outstanding
    31,871,502       21,839,209  
Employee Stock Purchase Plan
    5,972,977       2,979,321  
Future option grants
    1,100,358       6,696,841  
     
     
 
      39,991,065       32,561,599  
     
     
 
Shares subject to repurchase
    590,507       1,484,747  
     
     
 
 
Common Stock Warrants

      Transmeta has periodically granted warrants in connection with certain lease and bank agreements and consulting services. The Company had the following warrants outstanding to purchase common stock at December 31, 2002:

                           
Exercise
Number of Price per
Issuance Date Shares Share Expiration Date




October 1995
    60,196     $ 0.41       October 2005  
April 1997
    160,000     $ 1.25       March 2003  
January 1998
    125,032     $ 1.25       December 2007  
April 1998
    240,000     $ 1.25       April 2008  
April 1998
    320,000     $ 1.25       March 2004  
May 1998
    50,000     $ 3.00       May 2005  
March 1999
    68,000     $ 3.00       March 2004  
February 2000
    8,000     $ 5.00       February 2005  
March 2001
    15,000     $ 5.00       March 2005  
     
                 
 
Total number of shares
    1,046,228                  
     
                 

      All warrants have been valued using the Black-Scholes valuation model based on the assumptions used for stock-based awards to employees (see Note 11) except that a volatility of 0.80 was used was used through fiscal 2000. Assigned values of $30,000 and $17,000 associated with these warrant issuances were recorded as common stock in 2000 and 1999, respectively, and are being amortized as interest expense over the term of the agreement or the period the services are rendered. Costs associated with warrants issued during 2001 were deemed immaterial.

 
Treasury Stock

      In connection with the resignation of two officers in the fourth quarter of fiscal 2001, the Company purchased 796,875 mature vested shares with a market value of approximately $2.4 million held by the two officers in exchange for cancellations of a portion of shareholder notes held by the officers (see Note 11).

55


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Mature vested shares are shares that have been both vested and outstanding for over six months. As a result of this transaction, the Company has recorded $2.4 million as a contra-equity balance representing the market value of the treasury stock at the date the shares were acquired and the notes were cancelled.

 
Preferred Stock

      The Company is authorized, subject to limitations imposed by Delaware law, to issue up to a total of 5,000,000 shares of preferred stock in one or more series, without stockholder approval. The Board of Directors is authorized to establish from time to time the number of shares to be included in each series, and to fix the rights, preferences and privileges of the shares of each wholly unissued series and any of its qualifications, limitations or restrictions. The Board of Directors can also increase or decrease the number of shares of a series, but not below the number of shares of that series then outstanding, without any further vote or action by the stockholders.

      The Board of Directors may authorize the issuance of preferred stock with voting or conversion rights that could harm the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of Transmeta and might harm the market price of its common stock and the voting and other rights of the holders of common stock. As of December 31, 2002 and 2001, there were no shares of preferred stock outstanding.

 
Stockholders’ Rights Agreement

      On January 10, 2002, the Company entered into a Rights Agreement, pursuant to which the Company’s Board of Directors declared a dividend of one stock purchase right (a “Right”) for each outstanding share of the Company’s common stock. The dividend was issued to stockholders of record on January 18, 2002. In addition, one Right shall be issued with each share of the Company’s common stock that becomes outstanding (i) between the record date and the earliest of the Distribution Date, the Redemption Date and the Final Expiration Date (as such terms are defined in the Rights Agreement) or (ii) following the Distribution Date and prior to the Redemption Date or Final Expiration Date, pursuant to the exercise of stock options or under any employee plan or arrangement or upon the exercise, conversion or exchange of other securities of the Company, which options or securities were outstanding prior to the Distribution Date. The Rights will become exercisable only upon the occurrence of certain events specified in the Rights Agreement, including the acquisition of 15% of the Company’s outstanding common stock by a person or group. Each Right entitles the registered holder, other than an “acquiring person”, under specified circumstances, to purchase from the Company one one-hundredth of a share of Series A Junior Participating Preferred Stock, par value $0.00001 per share, of the Company, at a price of $21.00 per one one-hundredth of a share of that preferred stock, subject to adjustment. In addition, each Right entitles the registered holder, other than an “acquiring person”, under specified circumstances, to purchase from the Company that number of shares of the Company’s Common Stock having a market value of two times the exercise price of the Right.

11.     Stock-Based Compensation

 
2000 Equity Incentive Plan

      The 2000 Equity Incentive Plan (“the Plan”) was adopted in September 2000 and became effective November 6, 2000. The Plan serves as the successor to the 1997 Equity Incentive Plan, and authorizes the award of options, restricted stock and stock bonuses and provides for the grant of both incentive stock options (“ISO’s”) that qualify under Section 422 of the Internal Revenue Code and nonqualified stock options. The exercise price of the incentive stock options must be at least equal to the fair market value of the common stock on the date of grant. The exercise price of incentive stock options granted to 10% stockholders must be at least equal to 110% of the fair market value of the common stock on the date of grant. The maximum term of

56


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

the options granted is ten years. During any calendar year, no person will be eligible to receive more than 4,000,000 shares, or 6,000,000 shares in the case of a new employee.

      Transmeta initially reserved 7,000,000 shares of common stock under the Plan. The aggregate number of shares reserved for issuance under the Plan is increased automatically on January 1 of each year starting on January 1, 2001 by an amount equal to 5% of the total outstanding shares of the Company on the immediately preceding December 31. As a result of this provision, 6,611,728 and 6,520,946 shares were added to the Plan in 2002 and 2001, respectively. In addition, the Plan allows for canceled shares from the 1995 and 1997 Equity Incentive Plans to be transferred into the 2000 Plan. As a result of this provision, 3,116,323 and 1,508,882 shares were also added to the Plan in 2002 and 2001, respectively.

 
Non-Plan Stock Option Grants

      Transmeta has from time to time granted options outside of its plans (“non-plan stock options”). Non-plan stock options to purchase shares of common stock authorized and granted were 7,046,000 in 2000 and 2,500,000 in 1999. No non-plan stock options were granted in 2002 and 2001.

 
Prior Equity Incentive Plans

      The 1995 Equity Incentive Plan and the 1997 Equity Incentive Plan (the “Prior Plans”) provided for the grant to employees of ISOs and the grant to employees, directors and consultants of nonstatutory stock options. Options granted under the Prior Plans were designated as “ISO,” or “nonstatutory stock options” at the discretion of Transmeta, with exercise prices not less than the fair market value at the date of grant. Options granted under the Prior Plans generally vest 25% on the first anniversary of the vesting start date and then monthly over the next three years and expire ten years from the grant date.

57


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

 
Stock Option Summary

      The following is a summary of the Company’s stock option activity under the Plan, the Prior Plans and outside the plans, and related information:

                                   
Options Outstanding

Weighted Weighted
Shares Average Average
Available for Number of Exercise Grant Date
Grant Shares Price Fair Value




Balance at December 31, 1999
    6,094,136       8,694,960     $ 0.79          
 
Additional shares reserved
    16,046,000                        
 
Options granted
    (15,579,600 )     15,579,600     $ 5.96     $ 6.06  
 
Options exercised
          (6,028,857 )   $ 2.60          
 
Options canceled
    413,464       (1,659,157 )   $ 3.36          
     
     
                 
Balance at December 31, 2000
    6,974,000       16,586,546     $ 4.72          
 
Additional shares reserved
    8,029,828                        
 
Options granted
    (8,791,821 )     8,791,821     $ 3.62     $ 2.70  
 
Options exercised
          (1,670,589 )   $ 0.94          
 
Options canceled
    484,834       (1,868,569 )   $ 5.15          
     
     
                 
Balance at December 31, 2001
    6,696,841       21,839,209     $ 4.53          
 
Additional shares reserved
    9,728,051                        
 
Options granted
    (22,278,100 )     22,278,100     $ 1.94     $ 1.59  
 
Options exercised
          (1,187,191 )   $ 0.68          
 
Options canceled
    6,953,566       (11,058,616 )   $ 4.35          
     
     
                 
Balance at December 31, 2002
    1,100,358       31,871,502     $ 2.93          
     
     
                 

      The exercise prices for options outstanding and exercisable as of December 31, 2002 and their weighted average remaining contractual lives were as follows:

                                           
Outstanding

Exercisable
Weighted
Average Weighted Weighted
Remaining Average Average
Shares Contractual Exercise Shares Exercise
Range of Exercise Prices Outstanding Life Years Price Exercisable Price






As of December 31, 2002:
                                       
 
$0.13-$0.95
    6,781,925       8.8     $ 0.86       1,715,235     $ 0.61  
 
$0.97-$2.35
    5,109,209       9.4     $ 1.28       489,686     $ 1.37  
 
$2.38-$2.46
    7,624,676       9.2     $ 2.42       1,213,661     $ 2.38  
 
$2.48-$3.25
    6,067,020       8.7     $ 2.88       1,757,044     $ 3.07  
 
$3.49-$5.30
    2,091,356       7.5     $ 5.02       1,188,137     $ 5.09  
 
$6.00-$8.25
    2,642,812       7.6     $ 6.81       1,389,800     $ 6.79  
 
$9.50-$11.17
    1,260,833       7.8     $ 9.54       614,753     $ 9.53  
 
$12.03-$27.88
    293,671       8.3     $ 15.39       125,392     $ 15.62  
     
                     
         
 
$0.13-$27.88
    31,871,502       8.7     $ 2.93       8,493,708     $ 3.92  
     
                     
         

58


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

 
2000 Employee Stock Purchase Plan

      Transmeta effected the 2000 Employee Stock Purchase Plan (the “Purchase Plan”) in November 2000. The Purchase Plan allows employees to designate up to 15% of their total compensation to purchase shares of the Company’s common stock at 85% of fair market value. Upon effectiveness of the Purchase Plan, the Company reserved 2,000,000 shares of common stock under the Purchase Plan. In addition, the aggregate number of shares reserved for issuance under the Purchase Plan will be increased automatically on January 1 of each year starting on January 1, 2001 by an amount equal to 1% of the total outstanding shares of the Company on the immediately preceding December 31. As a result of this provision, 1,322,346 and 1,304,189 shares were added to the Purchase Plan in 2002 and 2001, respectively. In May 2002, the Company’s stockholders authorized an additional 4,000,000 shares to be available under the Purchase Plan. As of December 31, 2002, 2,833,558 shares had been issued under the Purchase Plan.

 
Deferred Stock Compensation

      Transmeta recorded deferred stock compensation of $46.0 million during 2000, representing the aggregate difference between the exercise prices of the options and the deemed fair values of common stock subject to the options as of the respective measurement dates. This amount is being amortized by charges to operations, using the accelerated graded method, over the four year vesting periods of the individual stock options. During 2002, 2001 and 2000, the Company recorded $3.6 million, $16.6 million and $13.1 million, respectively, of net amortization expense related to deferred stock compensation. The net amortization expense recorded during fiscal 2002 included a credit of $1.7 million for stock option cancellations resulting from the Company’s workforce reduction in the third quarter.

 
Accounting for Stock-Based Compensation

      The Company has elected to follow APB Opinion 25 and related interpretations in accounting for its employee and director stock-based awards because, as discussed below, the alternative fair value accounting provided for under SFAS 123 requires use of option valuation models that were not developed for use in valuing employee stock-based awards. Under APB Opinion 25, the Company recognizes no compensation expense with respect to awards if the exercise price equals or exceeds the fair value of the underlying security on the date of grant and other terms are fixed.

      Officer notes. In the fourth quarter of fiscal 2001, the employment of two officers terminated. In connection with the termination of their employment, the Company repurchased a total of 796,875 vested shares and 1,753,125 unvested shares held by these officers. These shares were originally issued in return for an aggregate of $8.0 million in recourse notes. As a result of the repurchase of these shares and the cancellation of the outstanding recourse notes and accrued interest, Transmeta recorded additional stock compensation expense of $1.2 million primarily to write-off accrued interest on the notes and an offsetting entry of $1.9 million to reverse stock compensation expense previously recognized on the unvested shares.

      Notes Receivable from Stockholders. Transmeta’s equity incentive plans permit, subject to approval by the Board of Directors, holders of options granted prior to March 1999 and certain holders of non-plan grants to exercise stock options before they are vested. Shares of common stock issued in connection with these exercises are subject to repurchase at the exercise price. Notes issued by employees to exercise stock options bear interest at rates ranging from 4.47% to 6.60% and have original terms of five years. Prior to the fourth quarter of fiscal 2001, all notes were full recourse and were recorded as a reduction of stockholders’ equity when issued.

      Recourse notes held by other officers and employees. At the time the above two officer notes were cancelled, other recourse notes for a total of $8.2 million, including $0.7 million of accrued interest, were outstanding. Because the Company did not enforce the recourse provisions of the notes for the officers that

59


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

resigned, which would have recouped all principal and interest, in the fourth quarter of 2001, the Company began to account for these remaining notes as if they had terms equivalent to non-recourse notes, even though the terms of these notes were not in fact changed from recourse to non-recourse.

      Transmeta will continue to record stock compensation expense on these stock awards until the notes are paid based on the current market value of its stock at the end of each accounting period. This variable stock compensation will be based on the excess, if any, of the current market price of its stock as of period-end over the purchase price of the stock award, adjusted for vesting and prior stock compensation expense recognized on the stock award. At December 31, 2002, the Company had 1,489,000 shares that are subject to variable stock compensation at prices ranging from $0.13 to $1.25 per share. During fiscal 2002, stock compensation included a credit of $1.8 million recorded to stock compensation expense due to a lower market price of our common stock at the end of fiscal 2002 compared to the end of fiscal 2001. During fiscal 2001, Transmeta recorded $2.5 million of variable stock compensation expense relating to these stock awards. In addition, the Company recorded additional stock compensation expense of $0.7 million to write-off all interest that had accrued under the other recourse notes. In the future, if the price of the Company’s stock increases $1 per share it will result in approximately $1.5 million of additional stock compensation expense, or if the stock decreases $1 per share it will result in a benefit (reduction) in stock compensation expense of approximately the same amount. Because variable stock compensation expense is calculated based on the current market value of the Company’s common stock at the end of each accounting period, future stock compensation expense for these variable stock awards could increase significantly in periods when the Company’s stock price rises, and could reverse and become a benefit in periods when the Company’s stock price falls. The Company also has an additional 1,100,000 shares that are subject to variable accounting if its stock price increases above approximately $11.50 per share. However, the Company has a call option on these shares that it intends to exercise before the stock price exceeds $11.50 per share and does not believe it will incur variable stock compensation on these shares.

      Fair value accounting for stock-based awards. The fair value for the Company’s stock-based awards is estimated at the date of grant using a Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, the Black-Scholes option-pricing model requires the input of highly subjective assumptions, including expected stock price volatility. Because the Company’s stock-based awards have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its stock-based awards. The fair value of options granted in 2000 was determined based on estimated stock price volatility. The weighted average assumptions used to determine fair value were as follows:

                                                 
Options ESPP


Years Ended Years Ended
December 31, December 31,


2002 2001 2000 2002 2001 2000






Expected volatility
    1.3       1.1       0.8       1.2       1.3       N/A  
Expected life in years
    4       4       4       .5       .5       N/A  
Risk-free interest rate
    3.7 %     4.4 %     6.5 %     2.5 %     4.0 %     N/A  
Expected dividend yield
    0       0       0       0       0       N/A  

      In connection with a severance agreement, the Company extended repayment terms of a note receivable secured by shares exercised from options previously granted. The Company remeasured the value of the options based upon the then fair value of the stock as determined by the Board of Directors. The resulting additional charge of $0.9 million was expensed as compensation in 2000.

60


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

12.     Employee Benefit Plan

      Transmeta has an Employee Savings and Retirement Plan (the “Benefit Plan”) under Section 401(k) of the Internal Revenue Code for its eligible employees. The Benefit Plan is available to all of Transmeta’s employees who meet minimum age requirements, and provides employees with tax deferred salary deductions and alternative investment options. Employees may contribute up to 15% of their eligible earnings, subject to certain limitations. There have been no matching contributions by the Company under the Benefit Plan.

13.     Income Taxes

      Transmeta has not recorded a provision for federal, state or foreign taxes during for fiscal years 2002, 2001 and 2000 as the Company has incurred operating losses in all periods that have not been tax benefited.

      Deferred income taxes reflect the net tax effect of operating losses and tax credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:

                         
Years Ended December 31,

2002 2001 2000



(in thousands)
Federal operating loss carryforwards
  $ 99,000     $ 67,400     $ 43,600  
State operating loss carryforwards
    5,000       5,400       5,400  
Federal tax credit carryforwards
    8,000       6,500       3,700  
State tax credit carryforwards
    6,000       3,300       2,000  
Non-deductible reserves and capitalized expenses
    35,000       29,600       4,040  
     
     
     
 
      153,000       112,200       58,740  
Less: Valuation allowance
    (153,000 )     (112,200 )     (58,740 )
     
     
     
 
Net deferred taxes
  $     $     $  
     
     
     
 

      Based upon the weight of available evidence, which includes the Company’s historical operating performance, the Company has always provided a full valuation allowance against its net deferred tax assets as it is not more likely than not that the deferred tax assets will be realized. The valuation allowance increased by $40.8 million in 2002, $53.5 million in 2001, and $33.0 million in 2000.

      The federal operating loss and tax credit carryforwards listed above will expire between 2010 and 2022, if not previously utilized. The state operating loss and tax credit carryforwards will expire beginning in 2004, if not previously utilized. Utilization of the Company’s net operating loss may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitation could result in the expiration of the net operating loss being utilized.

      The Company incurred pre-tax losses from foreign operations of $20.7 million, $14.0 million and $16.7 million in years 2002, 2001, and 2000, respectively.

14.     Segment Information

      Transmeta has adopted the FASB’s SFAS 131, “Disclosure About Segments of an Enterprise and Related Information”. Transmeta operates and is evaluated by management on a single segment basis; the development, marketing and sale of hardware and software technologies for the mobile computing market.

61


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Sales by geographic area are categorized based on the customers billing address. The following is a summary of the Company’s net product revenue by major geographic area:

                         
Years Ended
December 31,

2002 2001 2000



Japan
    79 %     67 %     83 %
Asia (except Japan)
    20 %     24 %     12 %
North America
    1 %     9 %     5 %

      The following customers accounted for more than 10% of total revenue:

                           
Years Ended
December 31,

2002 2001 2000



Customer:
                       
 
Sony Electronics
    37 %     30 %     60 %
 
Fujitsu
    26 %     12 %     28 %
 
Toshiba
    * %     18 %     * %
 
Siltrontech Electronics
    * %     11 %     * %


represents less than 10% of total revenue

15.     Legal Proceedings

      Beginning in June 2001, Transmeta, its directors, and certain of its officers were named as defendants in several putative shareholder class actions filed in the United States District Court for the Northern District of California.(1) The Court consolidated those complaints into a single action entitled In re Transmeta Corporation Securities Litigation, Case No. C 01-02450 WHA. In December 2001, plaintiffs filed their consolidated amended complaint. The consolidated amended complaints purported to allege a class action on behalf of all persons, other than the individual defendants and the other officers of Transmeta, who purchased or acquired common stock of Transmeta during the period from November 7, 2000 to July 19, 2001. The consolidated amended complaints alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder, and Sections 11 and 15 of the Securities Act of 1933, as amended. In March 2002, the Court granted in part and denied in part defendants’ motions to dismiss the consolidated amended complaint. In May 2002, the Court granted in part and denied in part defendants’ motion to dismiss the second amended complaint, and denied plaintiffs’ motion for leave to file a third amended complaint. In June 2002, defendants answered the second amended complaint as to the only surviving claim. In July 2002, defendants filed a motion for summary judgment relating to that claim. Plaintiffs moved for class certification, and the Court was scheduled to hear defendants’ motion for summary judgment and plaintiffs’ motion for class certification in December 2002. The Company believes that the


      1Hertzfeld, et al. v. Transmeta Corp., et al. (Case No. C-01-2450-JL, N.D. Cal.); Pond Equities v. Transmeta Corp., et al. (Case No. C-01-2463-JL, N.D. Cal.); McCarvill v. Transmeta Corp., et al. (Case No. C-01-2534-BZ, N.D. Cal.); Puente v. Transmeta Corp., et al. (Case No. C-01-2464-EDL, N.D. Cal.); Koroluk v. Transmeta Corp., et al. (Case No. C-01-2587-EDL, N.D. Cal.); Gammino v. Transmeta Corp., et al. (Case No. C-01-2614- EDL, N.D. Cal.); Dunnavant v. Transmeta Corp., et al. (Case No. C-01-20647-EDL, N.D. Cal.); LaFleur v. Transmeta Corp., et al. (Case No. C-01-03263 WHA, N.D. Cal.); Bernstein v. Transmeta Corp., et al. (Case No. C-01-03264 WHA, N.D. Cal.); and Shekleton v. Transmeta Corp., et al. (Case No. C-01-03291 WHA, N.D. Cal.).

62


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

allegations in the second amended complaint and the antecedent complaints are without merit and have defended the consolidated action vigorously. Notwithstanding this belief, and in order to avoid any additional waste of management time and expense, the Company and the individual defendants entered into a memorandum of understanding with plaintiffs’ counsel to settle all claims that might have been brought in this action for approximately $5.5 million, all of which monies have been paid by the defendants’ Directors and Officer (“D&O”) liability insurance. In December 2002, the court granted preliminary approval to the proposed settlement agreement. In March 2003, the Court granted final approval of the settlement agreement.

      Beginning June 2001, the directors and certain officers of Transmeta were sued in four purported shareholder derivative actions.(2) In October 2001, those cases were consolidated in and by the Superior Court for Santa Clara County in a single action entitled In re Transmeta Corporation Derivative Litigation, Master File No. CV 799491. In April 2002, plaintiffs filed a consolidated amended complaint. Like its antecedents, the consolidated amended complaint is based upon the same general allegations set out in the purported shareholder class actions described above. In May and June 2002, Transmeta and the individual defendants filed two demurrers to the second amended complaint. In July 2002, the Court sustained Transmeta’s demurrer based on plaintiffs’ lack of standing, gave plaintiffs 90 days to file an amended complaint, and deferred consideration of the individual defendants’ demurrer as moot. The Company believes that the allegations in the second amended complaint and its antecedents are without merit and have defended the action vigorously. Notwithstanding this belief, and in order to avoid any additional waste of management time and expense, the Company and the individual defendants agreed to settle all claims that might have been brought in this action for a sum of money to be paid entirely by defendants’ D&O liability insurance, similar to the proposed agreement to settle all of the claims in the federal class action. In December 2002, the parties executed a memorandum of understanding dated October 3, 2002 (the “MOU”). The MOU provides for a settlement of the consolidated derivative action pursuant to a definitive agreement and subject to judicial approval. The proposed settlement includes a dismissal with prejudice of all asserted claims, a release in favor of all defendants, and a payment to fees to counsel for the derivative plaintiffs in an amount to be approved by the Court but not to exceed $300,000. The court has scheduled a hearing on the proposed settlement for April 29, 2003.

      Beginning in June 2001, the Company, certain of its directors and officers, and certain of the underwriters for its initial public offering were named as defendants in three putative shareholder class actions filed in the United States District Court for the Southern District of New York. In January 2002, the Court ordered that all matters in the Southern District of New York be consolidated under In re Transmeta Corporation Initial Public Offering Securities Litigation, No. 01 CV 6492. On April 19, 2002, plaintiffs filed a consolidated amended complaint. The consolidated amended complaint alleges that the prospectus from Transmeta’s November 7, 2000 initial public offering failed to disclose certain alleged actions by the underwriters for the offering. The consolidated amended complaint alleges claims against Transmeta and several of its officers and directors under Sections 11 and 15 of the Securities Act of 1933, as amended, and under Sections 10(b) and Section 20(a) of the Securities Exchange Act of 1934, as amended. Other actions have been filed making similar allegations regarding the initial public offerings of more than 300 other companies. All of these consolidated cases have been coordinated for pretrial purposes as In re Initial Public Offering Securities Litigation, Master File No. 21 MC 92 (SAS). The Company believes that the allegations in the consolidated amended complaint and its antecedents are without merit and intend to defend the action vigorously. In November 2002, Transmeta joined a coordinated motion to dismiss filed on behalf of all issuers and individual


      2Pereira v. David Ditzel, et al. (Case No. CV 799491), Sweeney v. Mark Allen, et al. (Case No. CV 799667), and Scotter v. David Ditzel, et al. (Case No. CV 808264), all filed in Superior Court for Santa Clara County, California, and Krim v. David R. Ditzel, et al. (Case No. CV 418524), filed in Superior Court for San Mateo County, California, and later transferred to Santa Clara County pursuant to stipulated consolidation order.

63


Table of Contents

TRANSMETA CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

defendants. In March 2003, the Court granted in part and denied in part that coordinated motion to dismiss, and issued an order regarding pleading of amended complaints.

16.     Quarterly Results of Operations (Unaudited)

      The following table presents Transmeta’s unaudited quarterly statement of operations data for the four quarters of fiscal 2002 and fiscal 2001. The Company believes that this information has been prepared on the same basis as its audited consolidated financial statements and that all necessary adjustments, consisting only of normal recurring adjustments, have been included to present fairly the selected quarterly information. Transmeta’s quarterly results of operations for these periods are not necessarily indicative of future results of operations.

                                                                     
Quarters Ended

Dec. 31, Sept. 30, Jun. 30, Mar. 31, Dec. 31, Sept. 30, Jun. 30, Mar. 31,
2002 2002 2002 2002 2001 2001 2001 2001








(In thousands)
Net product revenue
  $ 6,118     $ 6,443     $ 7,539     $ 4,147     $ 1,462     $ 5,027     $ 10,531     $ 18,570  
Cost of revenue
    4,680       3,994       5,617       2,836       1,451       2,837       34,026       10,381  
     
     
     
     
     
     
     
     
 
Gross profit (loss)
    1,438       2,449       1,922       1,311       11       2,190       (23,495 )     8,189  
     
     
     
     
     
     
     
     
 
Operating expenses Research and development
    12,632       13,707       19,184       18,080       16,251       17,029       17,233       17,126  
 
In-process research and development
                                        13,600        
 
Selling, general and administrative
    6,991       6,255       8,737       7,934       8,835       8,776       8,861       8,990  
 
Restructuring charges
          4,102       10,624                                
 
Amortization of deferred charges, patent and patent rights
    2,848       2,848       2,848       2,848       5,044       5,024       4,109       3,379  
 
Impairment write-off of deferred charges
                            16,564                    
 
Stock compensation
    1,214       (1,651 )     (2,558 )     4,804       5,131       4,046       5,650       6,127  
     
     
     
     
     
     
     
     
 
   
Total operating expenses
    23,685       25,261       38,835       33,666       51,825       34,875       49,453       35,622  
     
     
     
     
     
     
     
     
 
Operating loss
    (22,247 )     (22,812 )     (36,913 )     (32,355 )     (51,814 )     (32,685 )     (72,948 )     (27,433 )
 
Interest and other income
    628       1,137       1,425       1,772       2,324       3,332       3,959       5,072  
 
Interest expense
    (67 )     (90 )     (140 )     (304 )     (218 )     (232 )     (265 )     (345 )
     
     
     
     
     
     
     
     
 
Net loss
  $ (21,686 )   $ (21,765 )   $ (35,628 )   $ (30,887 )   $ (49,708 )   $ (29,585 )   $ (69,254 )   $ (22,706 )
     
     
     
     
     
     
     
     
 
Net loss per share — basic and diluted
  $ (0.16 )   $ (0.16 )   $ (0.27 )   $ (0.23 )   $ (0.38 )   $ (0.22 )   $ (0.54 )   $ (0.18 )
     
     
     
     
     
     
     
     
 
Weighted average shares outstanding — basic and diluted
    136,850       135,561       133,868       132,997       130,874       131,560       128,478       125,970  
     
     
     
     
     
     
     
     
 

64


Table of Contents

 
Item 9.      Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

      Not applicable.

PART III

 
Item 10.      Directors and Executive Officers of the Registrant

      The information required by this Item is incorporated by reference to the captions “Election of Directors,” “Executive Officers” and “Compliance under Section 16(a) of the Securities and Exchange Act of 1934” in our Proxy Statement for our May 2003 Annual Meeting.

 
Item 11.      Executive Compensation

      The information required by this Item is incorporated by reference to the captions “Director Compensation,” “Executive Compensation” and “Compensation Committee Interlocks and Insider Participation” in our Proxy Statement for our May 2003 Annual Meeting.

 
Item 12.      Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

      This information required by this item is incorporated by reference to the caption “Principal Stockholders” in our Proxy Statement for our May 2003 Annual Meeting.

 
Item 13.      Certain Relationships and Related Transactions

      This information required by this item is incorporated by reference to the caption “Related Party Transactions” in our Proxy Statement for our May 2003 Annual Meeting.

 
Item 14.      Controls and Procedures

      Evaluation of Disclosure Controls and Procedures. Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of a date within 90 days prior to the filing date of this annual report (the “Evaluation Date”). Based on such evaluation, such officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective for recording, processing, summarizing and reporting information that we (including our consolidated subsidiaries) are required to disclose in our reports filed or submitted under the Exchange Act.

      Changes in Internal Controls. Since the Evaluation Date, there have not been any significant changes in our internal controls or, to our knowledge, in other factors that could significantly affect such controls. Our Chief Executive Officer and Chief Financial Officer evaluated our internal controls as of the Evaluation Date. Those officers have indicated that, since the Evaluation Date, there have not been any significant changes in our internal controls or, to their knowledge, in other factors that could significantly affect those controls.

65


Table of Contents

PART IV

 
Item 15.      Exhibits, Financial Statement Schedules and Reports on Form 8-K

      (a) The following documents are filed as part of this report:

        1. Financial Statements — See Index to Consolidated Financial Statements in Part II, Item 8.
 
        2. Financial Statement Schedules —

      All financial statement schedules have been omitted because the information required is not applicable or is shown in the Consolidated Financial Statements or notes thereto.

        3. Exhibits

      The following exhibits are filed herewith or incorporated by reference herein:

         
Exhibit
Number Exhibit Title


  3.01     Second Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.01 to Transmeta’s Form 10-K for the year ended December 31, 2000.
  3.02     Restated Bylaws. Incorporated by reference to Exhibit 3.06 to Transmeta’s Form S-1 Registration Statement (File No. 333-44030) (the “IPO S-1”).
  3.03     Certificate of Designations specifying the terms of the Series A Junior Participating Preferred Stock of Transmeta as filed with the Secretary of State of the State of Delaware on January 15, 2002. Incorporated by reference to Exhibit 3.02 to Transmeta’s Form 8-A Registration Statement filed on January 16, 2002.
  4.01     Specimen common stock certificate. Incorporated by reference to Exhibit 4.01 to the IPO S-1.
  4.02     Fifth Restated Investors’ Rights Agreement dated March 31, 2000, between Transmeta, certain stockholders of Transmeta and a convertible note holder named therein. Incorporated by reference to Exhibit 4.02 to the IPO S-1.
  4.03     Form of Piggyback Registration Rights Agreement. Incorporated by reference to Exhibit 4.03 to the IPO S-1.
  4.04     Rights Agreement dated January 15, 2002 between Transmeta and Mellon Investor Services LLC as Rights Agent, which includes as Exhibit A the form of Certificate of Designations of Series A Junior Participating Preferred Stock, as Exhibit B the Summary of Stock Purchase Rights and as Exhibit C the Form of Rights Certificate. Incorporated by reference to Exhibit 4.01 to Transmeta’s Form 8-A Registration Statement filed on January 16, 2002.
  10.01     Form of Indemnity Agreement. Incorporated by reference to Exhibit 10.01 to the IPO S-1.**
  10.02     1995 Equity Incentive Plan. Incorporated by reference to Exhibit 10.02 to the IPO S-1.**
  10.03     1997 Equity Incentive Plan. Incorporated by reference to Exhibit 10.03 to the IPO S-1.**
  10.04     2000 Equity Incentive Plan. Incorporated by reference to Exhibit 4.06 to Transmeta’s Form S-8 Registration Statement filed January 18, 2002.**
  10.05     2000 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 4.07 to Transmeta’s Form S-8 Registration Statement filed May 28, 2002.**
  10.06     Form of Option granted to Mark K. Allen and related documents. Incorporated by reference to Exhibit 10.06 to the IPO S-1.**
  10.07     Lease Agreement, dated November 1, 1995, between John Arrillaga, as trustee of John Arrillaga Family Trust, Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta, as amended by Amendment No. 1, dated January 29, 1997, and Amendment No. 2, dated April 2, 1998, between John Arrillaga, as trustee of John Arrillaga Survivor’s Trust (successor in interest to the Arrillaga Family Trust), Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta. Incorporated by reference to Exhibit 10.08 to the IPO S-1.

66


Table of Contents

         
Exhibit
Number Exhibit Title


  10.08     Lease Agreement, dated January 29, 1997, between John Arrillaga, as trustee of John Arrillaga Family Trust, Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta, as amended by Amendment No. 1, dated April 2, 1998, between John Arrillaga, as trustee of John Arrillaga Survivor’s Trust (successor in interest to the Arrillaga Family Trust), Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta. Incorporated by reference to Exhibit 10.09 to the IPO S-1.
  10.09     Lease Agreement, dated April 2, 1998, between John Arrillaga, as trustee of John Arrillaga Survivor’s Trust, Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta. Incorporated by reference to Exhibit 10.10 to the IPO S-1.
  10.10     Lease Agreement, dated April 2, 1998, between John Arrillaga, as trustee of John Arrillaga Survivor’s Trust, Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta. Incorporated by reference to Exhibit 10.11 to the IPO S-1.
  10.11     Sublease Agreement, dated as of April 28, 1999, between Transmeta and Xuan Nguyen dba World Marketing Alliance. Incorporated by reference to Exhibit 10.13 to the IPO S-1.
  10.12     Form of Stock Option Agreement under Transmeta’s 2000 Equity Incentive Plan. Incorporated by reference to Exhibit 10.17 to the IPO S-1.**
  10.13     Form of Stock Option Agreement (for Non-Employee Directors) under Transmeta’s 2000 Equity Incentive Plan. Incorporated by reference to Exhibit 10.18 to the IPO S-1.**
  10.14     Form of Stock Option Agreement. Incorporated by reference to Exhibit 10.18 to Transmeta’s Form 10-K for the year ended December 31, 2000.**
  10.15     Authorized Exclusive Distributor Agreement, dated September 12, 2000, between Transmeta and Siltrontech Electronics Corporation. Incorporated by reference to Exhibit 10.15 to Transmeta’s Form 10-K for the year ended December 31, 2001 (the “2001 10-K”).
  10.16     Full Recourse, Unsecured Promissory Note, dated April 10, 2001, between Transmeta and James Chapman. Incorporated by reference to Exhibit 10.16 to the 2001 10-K.**
  10.17     Option Amendment and Termination Agreement, dated November 16, 2001, between Transmeta and Merle McClendon. Incorporated by reference to Exhibit 10.17 to the 2001 10-K.**
  10.18     Stock Repurchase Agreement, dated November 27, 2001, between Transmeta, Mark Allen and Mark K. Allen and Valerie Allen as Trustees of the Allen Living Trust Dated 9/29/92. Incorporated by reference to Exhibit 10.18 to the 2001 10-K.**
  10.19     Stock Repurchase Agreement, dated November 27, 2001, between Transmeta, David Jensen and David P. Jensen and Debra A. Jensen as Trustees of the Jensen Family U/ D/ T Dated 4/23/97. Incorporated by reference to Exhibit 10.19 to the 2001 10-K.**
  10.20     Separation Agreement, dated as of December 11, 2001, between Transmeta and Mark Allen. Incorporated by reference to Exhibit 10.20 to the 2001 10-K.
  10.21     Separation Agreement, dated as of December 14, 2001, between Transmeta and David Jensen. Incorporated by reference to Exhibit 10.21 to the 2001 10-K.
  10.22     Offer of Employment from Transmeta Corporation to Matthew R. Perry dated March 21, 2002. Incorporated by reference to Exhibit 10.22 to Transmeta’s Form 10-Q for the quarterly period ended June 30, 2002.**
  21.01     Subsidiaries. Incorporated by reference to Exhibit 21.01 to the IPO S-1.
  23.01 *   Consent of Ernst & Young LLP, Independent Auditors.
  24.01 *   Power of Attorney. See Signature Page.
  99.01 *   Certification by Matthew R. Perry pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  99.02 *   Certification by Svend-Olav Carlsen pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

67


Table of Contents


Filed herewith.

**  Management contract or compensatory arrangement.

      (b) Reports on Form 8-K

        Not applicable.

      (c) Exhibits

        See Item 15(a)(3) above.

      (d) Financial Statement Schedules

        See Item 15(a)(2) above.

68


Table of Contents

SIGNATURES

      Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  TRANSMETA CORPORATION

  By:  /s/ SVEND-OLAV CARLSEN
 
  Svend-Olav Carlsen
  Chief Financial Officer
  (Principal Financial Officer and
  Duly Authorized Officer)

Dated: March 27, 2003

POWER OF ATTORNEY

      By signing this Form 10-K below, I hereby appoint each of Matthew R. Perry and Svend-Olav Carlsen, as my attorney-in-fact to sign all amendments to this Form 10-K on my behalf, and to file this Form 10-K (including all exhibits and other documents related to the Form 10-K) with the Securities and Exchange Commission. I authorize each of my attorneys-in-fact to (1) appoint a substitute attorney-in-fact for himself and (2) perform any actions that he or she believes are necessary or appropriate to carry out the intention and purpose of this Power of Attorney. I ratify and confirm all lawful actions taken directly or indirectly by my attorneys-in-fact and by any properly appointed substitute attorneys-in-fact.

      Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

             
Signature Title Date



 
/s/ MATTHEW R. PERRY

Matthew R. Perry
  Chief Executive Officer
[Principal Executive Officer]
  March 27, 2003
 
/s/ SVEND-OLAV CARLSEN

Svend-Olav Carlsen
  Chief Financial Officer
[Principal Financial Officer and
Duly Authorized Officer]
  March 27, 2003
 
/s/ MURRAY A. GOLDMAN

Murray A. Goldman
  Director   March 27, 2003
 
/s/ R. HUGH BARNES

R. Hugh Barnes
  Director   March 27, 2003
 


Larry R. Carter
  Director    
 
/s/ DAVID R. DITZEL

David R. Ditzel
  Director   March 27, 2003

69


Table of Contents

             
Signature Title Date



 
/s/ WILLIAM P. TAI

William P. Tai
  Director   March 27, 2003
 
/s/ T. PETER THOMAS

T. Peter Thomas
  Director   March 27, 2003

70


Table of Contents

CERTIFICATIONS

I, Matthew R. Perry, certify that:

      1. I have reviewed this annual report on Form 10-K of Transmeta Corporation;

      2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

      3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

      4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

        a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
 
        b) evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the “Evaluation Date”); and
 
        c) presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

      5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

        a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and
 
        b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and

      6. The registrant’s other certifying officers and I have indicated in this annual report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

  By:  /s/ MATTHEW R. PERRY
 
  Matthew R. Perry
  Chief Executive Officer
  (Principal Executive Officer)

Date: March 27, 2003

71


Table of Contents

CERTIFICATIONS

I, Svend-Olav Carlsen, certify that:

      1. I have reviewed this annual report on Form 10-K of Transmeta Corporation;

      2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

      3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

      4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

        a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
 
        b) evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this annual report (the “Evaluation Date”); and
 
        c) presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

      5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

        a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and
 
        b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and

      6. The registrant’s other certifying officers and I have indicated in this annual report whether there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

  By:  /s/ SVEND-OLAV CARLSEN
 
  Svend-Olav Carlsen
  Chief Financial Officer
  (Principal Financial Officer)

Date: March 27, 2003

72


Table of Contents

EXHIBIT INDEX

         
Exhibit
Number Exhibit Title


  3.01     Second Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.01 to Transmeta’s Form 10-K for the year ended December 31, 2000.
  3.02     Restated Bylaws. Incorporated by reference to Exhibit 3.06 to Transmeta’s Form S-1 Registration Statement (File No. 333-44030) (the “IPO S-1”).
  3.03     Certificate of Designations specifying the terms of the Series A Junior Participating Preferred Stock of Transmeta as filed with the Secretary of State of the State of Delaware on January 15, 2002. Incorporated by reference to Exhibit 3.02 to Transmeta’s Form 8-A Registration Statement filed on January 16, 2002.
  4.01     Specimen common stock certificate. Incorporated by reference to Exhibit 4.01 to the IPO S-1.
  4.02     Fifth Restated Investors’ Rights Agreement dated March 31, 2000, between Transmeta, certain stockholders of Transmeta and a convertible note holder named therein. Incorporated by reference to Exhibit 4.02 to the IPO S-1.
  4.03     Form of Piggyback Registration Rights Agreement. Incorporated by reference to Exhibit 4.03 to the IPO S-1.
  4.04     Rights Agreement dated January 15, 2002 between Transmeta and Mellon Investor Services LLC as Rights Agent, which includes as Exhibit A the form of Certificate of Designations of Series A Junior Participating Preferred Stock, as Exhibit B the Summary of Stock Purchase Rights and as Exhibit C the Form of Rights Certificate. Incorporated by reference to Exhibit 4.01 to Transmeta’s Form 8-A Registration Statement filed on January 16, 2002.
  10.01     Form of Indemnity Agreement. Incorporated by reference to Exhibit 10.01 to the IPO S-1.**
  10.02     1995 Equity Incentive Plan. Incorporated by reference to Exhibit 10.02 to the IPO S-1.**
  10.03     1997 Equity Incentive Plan. Incorporated by reference to Exhibit 10.03 to the IPO S-1.**
  10.04     2000 Equity Incentive Plan. Incorporated by reference to Exhibit 4.06 to Transmeta’s Form S-8 Registration Statement filed January 18, 2002.**
  10.05     2000 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 4.07 to Transmeta’s Form S-8 Registration Statement filed May 28, 2002.**
  10.06     Form of Option granted to Mark K. Allen and related documents. Incorporated by reference to Exhibit 10.06 to the IPO S-1.**
  10.07     Lease Agreement, dated November 1, 1995, between John Arrillaga, as trustee of John Arrillaga Family Trust, Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta, as amended by Amendment No. 1, dated January 29, 1997, and Amendment No. 2, dated April 2, 1998, between John Arrillaga, as trustee of John Arrillaga Survivor’s Trust (successor in interest to the Arrillaga Family Trust), Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta. Incorporated by reference to Exhibit 10.08 to the IPO S-1.
  10.08     Lease Agreement, dated January 29, 1997, between John Arrillaga, as trustee of John Arrillaga Family Trust, Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta, as amended by Amendment No. 1, dated April 2, 1998, between John Arrillaga, as trustee of John Arrillaga Survivor’s Trust (successor in interest to the Arrillaga Family Trust), Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta. Incorporated by reference to Exhibit 10.09 to the IPO S-1.
  10.09     Lease Agreement, dated April 2, 1998, between John Arrillaga, as trustee of John Arrillaga Survivor’s Trust, Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta. Incorporated by reference to Exhibit 10.10 to the IPO S-1.
  10.10     Lease Agreement, dated April 2, 1998, between John Arrillaga, as trustee of John Arrillaga Survivor’s Trust, Richard T. Peery, as trustee of Richard T. Peery Separate Property Trust, and Transmeta. Incorporated by reference to Exhibit 10.11 to the IPO S-1.
  10.11     Sublease Agreement, dated as of April 28, 1999, between Transmeta and Xuan Nguyen dba World Marketing Alliance. Incorporated by reference to Exhibit 10.13 to the IPO S-1.


Table of Contents

         
Exhibit
Number Exhibit Title


  10.12     Form of Stock Option Agreement under Transmeta’s 2000 Equity Incentive Plan. Incorporated by reference to Exhibit 10.17 to the IPO S-1.**
  10.13     Form of Stock Option Agreement (for Non-Employee Directors) under Transmeta’s 2000 Equity Incentive Plan. Incorporated by reference to Exhibit 10.18 to the IPO S-1.**
  10.14     Form of Stock Option Agreement. Incorporated by reference to Exhibit 10.18 to Transmeta’s Form 10-K for the year ended December 31, 2000.**
  10.15     Authorized Exclusive Distributor Agreement, dated September 12, 2000, between Transmeta and Siltrontech Electronics Corporation. Incorporated by reference to Exhibit 10.15 to Transmeta’s Form 10-K for the year ended December 31, 2001 (the “2001 10-K”).
  10.16     Full Recourse, Unsecured Promissory Note, dated April 10, 2001, between Transmeta and James Chapman. Incorporated by reference to Exhibit 10.16 to the 2001 10-K.**
  10.17     Option Amendment and Termination Agreement, dated November 16, 2001, between Transmeta and Merle McClendon. Incorporated by reference to Exhibit 10.17 to the 2001 10-K.**
  10.18     Stock Repurchase Agreement, dated November 27, 2001, between Transmeta, Mark Allen and Mark K. Allen and Valerie Allen as Trustees of the Allen Living Trust Dated 9/29/92. Incorporated by reference to Exhibit 10.18 to the 2001 10-K.**
  10.19     Stock Repurchase Agreement, dated November 27, 2001, between Transmeta, David Jensen and David P. Jensen and Debra A. Jensen as Trustees of the Jensen Family U/ D/ T Dated 4/23/97. Incorporated by reference to Exhibit 10.19 to the 2001 10-K.**
  10.20     Separation Agreement, dated as of December 11, 2001, between Transmeta and Mark Allen. Incorporated by reference to Exhibit 10.20 to the 2001 10-K.
  10.21     Separation Agreement, dated as of December 14, 2001, between Transmeta and David Jensen. Incorporated by reference to Exhibit 10.21 to the 2001 10-K.
  10.22     Offer of Employment from Transmeta Corporation to Matthew R. Perry dated March 21, 2002. Incorporated by reference to Exhibit 10.22 to Transmeta’s Form 10-Q for the quarterly period ended June 30, 2002.**
  21.01     Subsidiaries. Incorporated by reference to Exhibit 21.01 to the IPO S-1.
  23.01 *   Consent of Ernst & Young LLP, Independent Auditors.
  24.01 *   Power of Attorney. See Signature Page.
  99.01 *   Certification by Matthew R. Perry pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  99.02 *   Certification by Svend-Olav Carlsen pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


Filed herewith.

**  Management contract or compensatory arrangement.